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Vascular Dementia (VaD) is an important public health concern, which causes significant 
morbidity and mortality amongst populations around the world.  With the increases in average age 
of individuals and prevalence of cardiovascular risk factors, the incidence of vascular cognitive 
impairment (VCI) and VaD are on the rise.  Most of this increase will come from cerebral small 
vessel disease (CSVD) as treatment for large vessel disease improves.  Yet, very few interventions 
are recommended for CSVD beyond control of risk factors.  
In this thesis, we propose a non-pharmacological intervention, which we believe may 
address executive dysfunction in VCI due to CSVD.  CSVD impairs functional frontal-subcortical 
connectivity and results in cognitive and functional impairments. Given the plasticity in these 
circuits, despite old age, cognitive training may be a good candidate for improving cognition in 
CSVD.  However, previous studies have suffered from heterogeneity of pathologies in VCI by 
including both large and small vessel disease.  Furthermore, they have often not considered the 
effects of anxiety and depression, which we aim to exclude from the study.  Finally, these studies 
do not use validated composite scores as a primary endpoint and currently do not use any 
biomarkers to follow the progress of subjects. In this study, we aim to partially address these 





Chapter 1 – Introduction 
1.1 Background: Vascular Dementia 
1.2 Vascular Dementia: Large vessel vs. small vessel disease 
Vascular dementia (VaD) is a widely recognized public health concern which imposes 
significant clinical, social, and financial burdens on society.  Vascular dementia is the second most 
common form of dementia after Alzheimer’s Disease (AD).  Its prevalence in the United States is 
reported to be 8-10%,1 but this is likely to be an underestimation given that most cases of mixed 
vascular and Alzheimer’s pathology are reported as AD.2  Currently, research into VaD is in its 
infancy with definitive diagnostic criteria and biomarkers still in development.  Research into VaD 
is a critical and urgent area of medical research since VaD is shown to lower median life 
expectancy, create greater health care expenditures, and have higher rates of comorbidity when 
compared to AD.1  
VaD is the result of vascular brain injury from large vessel strokes or cerebral small vessel 
disease (CSVD).  There are important distinctions between these two categories as they are distinct 
diseases and require different approaches: Large vessel disease is caused by lesions in the setting 
of a large vessel becoming occluded.  All large vessels and their tributaries may suffer from strokes 
including branches of the carotids, anterior, middle, and posterior cerebral arteries.  Occlusion may 
occur due to cardioembolic, arterioembolic, or atherosclerotic etiologies.  Large vessel strokes can 
affect cognition proportionate to the extent of damage they cause to the brain.  In contrast, “strategic 
infarcts” can cause severe cognitive deficits by anatomically limited lesions when they affect highly 
connected areas of the brain networks.  These include the anterior and median thalamus, medial 
temporal lobes, basal ganglia, angular gyrus, and the fornices.3 Treatment strategies for strokes are 
well established. In the acute setting, thrombolysis and endovascular interventions may be 
considered, to reverse vessel occlusion.  In the immediate post-stroke period, stroke rehabilitation 




Multidisciplinary interventions are commonly implemented, and include exercise, cognitive 
training, and learning compensatory strategies.4 There is evidence that constraint-induced 
movement therapy, mental practice, mirror therapy, and high doses of repetitive exercises are 
effective in regaining motor function.5  
Cerebral small vessel disease is patho-physiologically distinct from large vessel disease.  
CSVD was originally thought to be an accumulation of small strokes,6 however this paradigm has 
been abandoned as large vessel disease treatments proved to be ineffective in CSVD.7 We have 
learned that CSVD is a heterogenous disease that can damage the cerebral vasculature by different 
pathological processes. Different pathologies may be at play in CSVD.  These pathologies are 
sorted into six broad categories based on their etiology in the Pantoni classification system which 
includes arteriosclerosis, cerebral amyloid angiopathy, hereditary angiopathies, inflammatory 
angiopathy, venous collagenosis and others.8  
In this project, we will confine our interest to CSVD caused by arteriosclerosis, cerebral 
angiopathy, and micro embolism.  These represent the increasingly common “white matter disease” 
seen in memory clinics.  Stroke rehabilitation is well characterized and established.  The role of 
non-pharmacological intervention in CSVD is less well established and may represent a major new 
way in which CSVD is managed.  
 Several lesions related to CSVD appear to contribute to the pathophysiology of cognitive 
disorders.  One category is that of lacunar infarcts.  Lacunar infarcts are small, non-cortical infarcts, 
of about 0.3 mm to 15 mm in size, that result from a small, single penetrating branch from a large 
cerebral artery becoming occluded.9  These occluded branches tend to be acutely angled and stem 
from the Circle of Willis, causing lacunar infarcts to have a predilection for the basal ganglia, 
subcortical white matter, and the pons.10 Lacunar infarcts are reported to account for 15% to 26% 
of ischemic strokes.11 These lacunar infarcts preferentially affect the cortico-subcortical circuitry 




Other pathologies include cerebral amyloid angiopathy, which is caused by the deposition 
of amyloid in small vessels.  For most part, this causes occlusion of small vessels especially in the 
partieto-occipital white matter.12  It also increases the risk of microhemorrhages seen preferentially 
in the posterior fossa.12 Enlarged perivascular spaces are another marker of vascular disease.  
Finally white matter hyperintensities represent various vascular related pathologies.8 
1.3 Current therapeutic approaches to CSVD 
Presently there are no interventions for cognitive impairment caused by CSVD which are 
strongly rooted in evidence.  Short of a disease modifying strategy, approach to the cognitive effects 
of CSVD probably fall into the following categories: 
- Secondary prevention measures addressing vascular pathology: 
o Pharmacological: For example, there is good evidence that strict blood pressure 
control may slow the progression of CSVD and its cognitive consequences.13  The 
evidence for other vascular risk factors is less strong. 
 
o Exercise and diet: Aerobic-based exercise in the acute period improved memory 
moderately, but long-term exercise, defined as 14 months, did not.14 Aerobic 
intervention however has been associated with stimulating the release of factors 
that promote dynamic network connectivity and neuro-vasculature protection, like 
brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and 
insulin-like growth factor (IGF-1).15  
 
- Interventions to improve cognition: 
o Pharmacological: there is evidence that cholinesterase inhibitors have a modest 
effect on cognition in CSVD.16,17  
 
o Non-pharmacological: Cognitive training was shown in one study to improve 
cognitive function up to five years post-training in the elderly with healthy 
cognitive functions.18 A Cochrane review found it to have only small beneficial 
effects in people with mild-to-moderate AD and VaD for cognitive rehabilitation 
and not cognitive training, but the quality of the studies were graded as low-to-
moderate.19  In the Cochrane review on Attention Process Training, small benefits 
were found in performing activities of daily living.20  Studies also found a relative 
association between attentional processes and behavioral outcomes.21  
 
- Treatment of neuropsychiatric comorbidities: Improvements in depression and anxiety will 
prevent against cognitive decline because psychiatric diseases can increase one’s risk for 






1.4 The Science Underlying our Proposed Experiment  
1.5 Network disruption in CSVD 
  CSVD affects white matter preferentially, and as such, can be seen in terms of changing 
connectivity in the brain.  CSVD has a predilection for interruption of frontal-subcortical 
circuitry.24 Frontal-subcortical impairment is characterized by prominent deficits in executive 
functioning, mentation speed, memory retrieval, attention25, as well as gait apraxia26, bladder 
dysfunction, pseudobulbar affect, apathy27, and depression28. 24 
Classically the frontal-subcortical circuitry are divided into five sub-circuits, three of which 
seem particularly vulnerable to CSVD: the dorsolateral prefrontal circuit, anterior cingulate circuit, 
and the orbitofrontal circuit. 29 These circuits send afferent projections to the thalamic nuclei, basal 
ganglia, or amygdalate nuclei, and send efferent projections to the inferotemporal, posterior 
parietal, or pre-striate cortices.29 Collectively, disruptions to these circuits have persistently 
presented with deficits in executive functions, apathy, and impulsivity.29  
More specifically, disruptions to these individual circuitries, or functional networks, will 
present with specific-behavioral deficits.  Dorsolateral prefrontal dysconnectivity is associated with 
poor behavioral responses because it can no longer organize the information that is integrated into 
task-related actions.29 Anterior cingulate dysconnectivity is associated with poor motivational 
behavior.29 Orbitofrontal circuit dysconnectivity is associated with emotional dysregulation 
because it integrates limbic and emotional information into behavioral responses.29  
Given that CSVD causes disruption of brain’s neural networks, one approach to improving 
task-specific performance may be adaptive changes, both functional and structural, to the network.  






The definition of neuroplasticity is varied and evolving.  Neuroplasticity refers to adaptive 
changes in brain connectivity and structures in response to experience.  The oldest conception of 
plasticity belongs to Donald Hebb who discovered that concurrent activation of both pre- and post- 
synaptic neurons causes strengthening of synaptic connection.  This is sometimes expressed as 
“neurons that fire together, they wire together.”30 More broadly, neuroplasticity may involve 
changes in synaptic strength or neuronal excitability. These can occur due to changes in the 
probability of neurotransmitter release and/or changes in receptor density.31 In the short term, 
plasticity is protein synthesis independent.31  In the long term, there are transcriptional changes 
which can target individual dendritic spines.31  Dendritic spines are highly dynamic: they are 
created and either grow, shrink or disappear.31 Dendritic spine turnover increases during 
adolescence, stimulation and exercise.31  Often-used dendritic spines consolidate, while rarely used 
connections are pruned.31 These, along with mechanisms that change synaptic strength and 
neuronal excitability, represent important mechanisms by which the brain learns and compensates 
for damage.  Experience-induced neuroplasticity may be useful in ‘rewiring” damaged networks.31   
The properties of experience-induced neuroplasticity were summarized by Kleim and 
Jones.32  Here we paraphrase and summarize their list as follows: 
- General premise:32  
o Synaptic density and neuronal excitability decrease with disuse of brain function 
and increase with use.   
o Changes that occur within used and unused networks are specific for brain 
function.  
 
- Dosing: plasticity occurs for skillful tasks performed at: 32 
 
o High repetition 
o High intensity  
o Sufficient duration of time   
 
- Optimization: Plasticity is most effective: 32  
 
o In particular windows of time, including brain damage  




o In younger subjects 
 
- Interaction with other domains:32 
 
o Transference: the property that training for one brain function will improve 
similar brain functions using similar anatomical structures. 
o Interference: that improvement in one brain function may be detrimental to the 
performance of another function. 
 
One particular form of plastic changes in neuronal excitability relates to the connections in 
layer III of the prefrontal cortex.33 Arnsten and others have worked extensively on this 
phenomenon, which they have termed Dynamic Network Plasticity.33 The basic premise is that high 
levels of norepinephrine cause reduced neuronal excitability, and in essence, will cause reduction 
in functional connectivity.33,34  This is significant for our purposes because fluctuations in anxiety 
from day-to-day may confound any measurement of connectivity in subjects.  We will now turn 
our attention to the techniques which we hope to employ in this experiment. 
1.7 Intervention 1: Dual N-Back 
 
 Dual N-Back is one of the most studied types of adaptive brain training.  It is a game in 
which participants are presented with two series of stimuli, and the task is to decide whether the 
current stimulus matches with the one presented n-items back.  The goal is to increase task-
difficulty level, which is adjusted to one’s performance.  In the Dual N-Back model, the ability to 
manipulate two tasks simultaneously is possible because of working memory and the coordinated 
interactions between the prefrontal cortex (PFC) and the basal ganglia (BG).35 
Increase in task-difficulty is an important feature of Dual N-Back because of its 
associations with greater learning and structural change.  Cognitive loading involves modulation 
and recruitment of additional networks when completing complex tasks or when other networks 
have become compromised.36-39 Cortical areas recruited by Dual N-Back include the 
lateral premotor cortex; dorsal cingulate and medial premotor cortexes; dorsolateral and 
ventrolateral prefrontal cortexes; frontal poles; medial and lateral posterior parietal cortexes and 




Involvement of frontoparietal, striatal, and thalamic regions support the possibility of 
cognitive transfer gains to other cognitive domains.41 This is supported by improvements in 
attention42,43, reasoning, and the ability to solve novel problems (“fluid intelligence”) after playing 
Dual N-Back.44 Executive functioning  is believed to be dependent on working memory, attention, 
and episodic memory retrieval,45 which are cognitive domains that have been strengthened by Dual 
N-Back.42,44,46 Executive functioning is also likely to improve more directly since Dual N-Back 
strengthens the frontoparietal network.47  
Adaptive cognitive trainings have shown only  modest improvements in cognition of the 
elderly with mild cognitive impairment (MCI) and dementia.19 The small effect size may be due 
to one of the following: 
1) Incorrect experimental design: problems with placebo-task, dosing, patient selection, 
or outcome measurements. 
2) Short-comings of the modality used.  
3) A lack of efficacy for adaptive cognitive training in general.   
 
1.8 Intervention 2: Mindfulness meditation 
 
In a “state of mindfulness,” a person becomes purposefully and nonjudgmentally aware of 
the present moment by learning acceptance and how to be actively present.48 Mindfulness is rooted 
in Buddhist philosophy and has various implementations in medical literature. Mindfulness 
meditation practice focuses attention on one’s own breathing while increasing awareness of the 
streams of information of both internal and external stimuli.48   
The purpose of mindfulness training is the deactivation of the default mode network.49,50  
The default mode network consists of the hippocampus and its connections to the posterior 
cingulate cortex and precuneus posteriorly, and its connections to the anterior cingulate cortex and 
mesial frontal lobes anteriorly.50  It is thought to consist of self-generated thoughts including un-
cued memories and day-dreaming.50  Default mode network can be thought of as “internal 
attention” compared to the dorsal attention network51 engaged in the Dual N-Back task.50 A loss of 




practiced forms of meditation seem to reduce default mode network activity leading to improved 
attentional function.50  
1.9 Combining the two interventions 
 
Combining the two interventions, one which activates the dorsal attention network and the 
other which deactivates the counter-correlated network, may create a synergistic effect which may 
be more efficacious than the other two methods on their own.   
1.10 Designing the experiment:   
1.11 Our experiment 
We hypothesize that subjects with mild vascular cognitive impairment (mild-VCI) who 
receive combined Dual N-Back and Mindfulness Meditation Practice (MMP) will have improved 
executive functioning capacities compared to those treated with placebo.  
Primary outcome is executive functioning capacity, and it is defined as mean change in 
executive functioning scores from baseline to one-year post-treatment initiation, as measured 
through Alzheimer's Disease Neuroimaging Initiative (ADNI)- Executive Function (ADNI-EF) 
test.  The mean changes will be reported as a Z score.  
Secondary aims include the following: 
1) Show increased connectivity in the high-performance network as defined by 
connectome predictor modeling (CPM) methodology. 
2) Explore improvements in other neuropsychological parameters. 
1.12 An imaging biomarker: A network approach to CSVD  
A network is a representation of a number of interconnected objects with nodes 
representing the objects and the edges representing the connections.52,53 The degree of connectivity 
may be represented by connection strength.52,53  We can simplify the relationship between the 
different cortical and subcortical structures connected by white matter tracts we discussed in the 
last section in terms of a network. 52,53 We can then explore the relationship between individual 




simplified by keeping only those edges that have a high positive or negative correlation with the 
performance of the particular task in question.52,53 These can respectively be called high-
performance network and low-performance network.52,53 Strengthening of low-performance 
network could potentially diminish behavioral performance, despite stability in high-performance 
networks. It is theoretically possible by manipulating the strength of connections in the network to 
change performance.52,53 
 
1.13 Definitions or Terminology 
 
1) VCI is the spectrum of the cognitive disorder that ranges from mild cognitive impairment 
(MCI) to dementia.2 
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Cerebral small vessel disease is an understudied population.  The medical community 
still has more to learn about its pathophysiology, and its diagnostic criteria is still being refined.  
We know that CSVD disrupts the frontal-subcortical circuitry1 and can present with deficits in 
executive functioning, mentation speed, memory retrieval, and attention2, along with other 
impairments, but we do not currently know how to best treat this disease.  
2.2 Objectives 
 
In this literature review, we will be assessing the clinical efficacy of Mindfulness 
Meditation and Dual N-Back versus an active-placebo control group on delaying executive 
functioning decline in people with MCI-CSVD.  We will also review Donepezil and other 
nonpharmacological interventions that are being studied on trying to improve cognitive 
functioning in MCI disease. 
   
2.3 Methods: Criteria for considering studies for this review 
2.4 Search Methods and Selection Criteria 
We searched ClinicalTrials.gov and Cochrane databases up until July 1, 2018, to identify 
relevant, peer-reviewed, primary articles of clinical RCT’s and systematic reviews of non-
pharmacological interventions in the treatment of VCI; treatments in CSVD population was too 
narrow of a search.  
In ClinicalTrials.gov, the terms “Vascular Cognitive Impairment,” “Cognitive 
dysfunction,” “Cognitive decline,” and “Vessel” were used.  We searched for completed, clinical 
trials with published results and found only four studies.  The interventions used were NA-13, a 
peptide that is designed to reduce ischemic brain damage in post-stroke patients, vitamin B4, calf-




hydrochlorothiazide.6  No non-pharmacological interventions populated, so studies from this 
search were not used.  
In Cochrane database, we used the MeSH Terms “Cognitive Dysfunction (vascular 
cognitive impairment),” “Dementia,” and “Vascular (subcortical dementia).”  We included all 
randomized trials of non-pharmacological interventions that are relevant to current practice 
guidelines in MCI treatment.7  The interventions outcomes had to include cognition or 
anxiety/stress.  All trials selected must have had published results.  
2.5 Types of Participants 
Participants were either cognitively healthy or elderly with MCI or dementia due to AD 
or VAD.  Studies that included healthy participants were to study the intervention’s effects on 
synaptic plasticity.   
2.6 Types of Interventions 
Cognitive Training.  We included studies that used Dual N-Back or other similar forms of 
adaptive cognitive training.  Interventions could be delivered individually or in groups.  The 
studies included come from Cochrane: “Cognitive training and cognitive rehabilitation for 
persons with mild to moderate dementia of the Alzheimer's or vascular type: a review”8 and from 
“Benefits of Cognitive Treatments Administered to Patients Affected by Mild Cognitive 
Impairment/Mild Neurocognitive Disorder.”9 
Mindful Meditation Practice.  We included trials that used MBSR or its modified 
versions.   
Donepezil.  We included all randomized, double‐blinded trials that compared donepezil 
with placebo.  Participants enrolled had VCI, which had to be confirmed by either NINCDS‐






2.10 Types of Outcome Measures  
 
We assessed the following outcomes when applicable.  Please refer to the appendix section for 
more information on the studies that are included in this review. 
1) Interventions effects on executive functioning scores 
2) Interventions effects on stress  
3) Interventions effects on brain activity assessed by imaging  
4) Interventions effects on other neurocognitive or behavioral domains 
5) Connectome Predictor Modeling 
 
 
2.11 Results  
2.12 Description of studies: Cognitive training, MMP, and Donepezil  
 Only one study was identified that compared MMP, cognitive training, and Donepezil’s 
effects on cognition in the elderly with mild-to-severe AD (Quintana-Hernández DJ).10 The two-
year, double-blinded RCT was an equivalency and non-inferiority study that compared MMP-
Donepezil to Cognitive Stimulation Training (CST)-Donepezil and Donepezil-only in delaying 
cognitive decline in AD.  The study enrolled 168 patients with mild-to-severe AD that was 
confirmed by the NINCDS-ARDA criteria.  The inclusion criteria limited the trial to patients who 
were older than 65 years-old, scored between 3-5 points on the GDS, and never had been 
prescribed Donepezil before.  The study controlled for education, age, APOE biomarker, HTN, 
diabetes, dyslipidemia, psychiatric diseases, antidepressants, and anxiolytics.  Some of the 
exclusion criteria included dementia or behavioral disorders like agitation. 
Risk of bias: The effects of the intervention appear to be true since there were no baseline 
differences across groups in cognition, sociodemographic factors, or clinical variables.  The study 
blinded participants by making them unaware of the other non-pharmacological interventions.  
Outcomes may be affected by informational biases, as MMP was the only single-blinded 
procedure because class sessions were conducted by the main researcher.    
Effects of intervention: The MMP-Donepezil group had significantly higher CAMCOG 




CST-Donepezil group (Repeated-measures, p<0.05).10  CAMCOG and MMSE measure spatial 
memory, language, memory, perception, attention, and praxia.10    
2.13 Description of studies: Combined MMP and Dual N-Back 
Only one study was identified that studied MMP and Dual N-Backs’ effects on attention 
and worrisome behavior (Course-Choi).11 The weeklong, non-clinical RCT enrolled 86 healthy 
adults with worrisome traits and randomized 15 participants to MMP-Dual N-Back, 15 
participants to the sham-control group (non-adaptive 1-back task), 15 participants to MMP, and 
15 participants to Dual N-Back. The inclusion criteria limited the trial to participants who were 
older than 17 years-old and scored higher than 44 on the Pennsylvania State Worry Questionnaire 
(PSWQ).  The study controlled for baseline differences in PSWQ scores, age, and gender.  
Risk of bias: The effects of the intervention appear to be true because the study was 
single-blinded, participants were randomized, and intention-to-treat analyses were run.  The 
observed outcomes    
are more likely true because the study controlled for baseline differences in worrisome and 
attention scores and sociodemographic variables, but it did not control for baseline differences in 
prior experiences with MMP or Dual N-Back.  The study found a near significant correlation 
between trait worry scores and Dual N-Back performance: Individual differences in performance 
could have affected results at a group level, preventing the between group’s analysis from 
detecting significance.  Also, the study was short and training times are associated with greater 
cognitive gains.12  However, worry score outcomes may be over-estimated because they were 
measured by STAI (self-reports). In addition, practice-effects in the active-control group could 
have confounded results. 
Effects of intervention: Combined MMP and Dual N-Back suggest long-term positive 




2.14 Description of studies: Adaptive Cognitive Training  
Studies conducted by Willis13, S. Salminen, T. (2016)14 Zhang, Y.15 and Salminen 
(2016)16 were included in this review.  Willis, Salminen, and Salminen, T. (2016) conducted 
single-blinded RCT’s, while Zhang’s randomization and blinding methods were not disclosed.  
Willis13 conducted a large-scale trial that examined cognitive trainings effects in healthy, 
elderly participants.  The studies outcomes were improvements in functional performance and 
cognition five-years, post-cognitive training.  The study enrolled 2802 participants aged 65 years 
or older.  The inclusion criteria limited the trial to participants who had mild functional 
impairments (<2 ADL disabilities), MMSE scores >23, and were unlikely to have dementia.  The 
study controlled for sex, education, age, health status, and MMSE and Short-Form-36-Physical 
Function scores.13   
Salminen (2016)14’s RCT examined Dual N-Back’s effects on executive functioning 
gains in the elderly.  The study enrolled 47 healthy, elderly participants aged 55 years or older.  
The inclusion criteria limited the trial to participants who had MMSE scores >28, Mehrfachwahl-
Wortschatz-Intelligenz test scores >110, and participants who did not have visual or auditory 
impairments.  The study controlled for cognitive differences at baseline, years of education, age, 
gender, and hand dominance.  
Zhang, Y.15 conducted an investigational trial that first assessed if there are functional 
connectivity differences between controlled, Type-II Diabetics (T2DM) and euglycemics, and if 
single-back could modify working memory (WM)’s functional systems.  The study enrolled 20 
cognitively healthy, T2DM and enrolled 19 matched euglycemic patients.  The inclusion criteria 
limited the study to T2DM without complications, MMSE scores >27, and participants had to 
screen negative for metabolic syndromes, cerebrovascular events, and history of substance 
use.  The study controlled for clinical variables (HbA1c, lipid panel, and HTN), cognitive status 




(Self-Rating Anxiety Scale and Self-Rating Depressive Scale), Short-term memory 
performance (AVLT Test scores), age, gender, and education. 
Salminen, T. (2016)16’s RCT assessed Dual N-Back’s effects on white matter integrity in 
healthy participants.  The study enrolled 56 participants and randomized 20 participants to Dual 
N-Back, 18 participants to single-back active control group, and 18 participants to the control 
group-no contact.  The study did not discuss its inclusion criteria in detail, but it did reference 
enrolling people with normal vision and hearing and right-hand dominance.  The study controlled 
for age, sex, and baseline performance scores.  
Risk of bias: The effects of the interventions appear to be reliable because the studies 
included were randomized, single-blinded, and ran intention-to-treat analyses, except for the 
investigational study.  There were also no baseline differences across groups in age, gender, 
education, clinical variables, cognitive variables, and adherence to protocol.  
Willis reported a 67% retention rate by the end of the five-year study, but the missing 
data did not significantly affect result outcomes, as supported by the multiple-imputation 
calculation on missing data.13  Due to the large sample size, Willis’s study should have 
determined if a smaller sample size could have detected significant results.13 
Salminen (2016) found significant improvements in executive functioning scores in the 
elderly Dual N-Back group.  To show that Dual N-Back caused this effect, he ran a MANOVA, 
which was found to be significant (Group x Session x Age, F(10, 67) = 3.38, p < .005, η2 p = 
.34).14   
Zhang, Y. supported significant findings by running statistical analyses.  He confirmed 
that the increase in brain activity was occurring in WM systems by running a voxel-wise one-
sample t-test across the spatial components of the WM networks (p<0.05).15  The inclusion of 
the component analysis also strengthened the study’s findings because it can reveal hidden 
factors that underlie sets of random variables, measurements, and signals.15  The study may have 




Salminen, T. (2016) used only quality images in his study, but outcomes may have been 
affected by not controlling for baseline differences in white matter integrity between groups.16 
Effects of the interventions: Willis’s study found that Memory (effect size, 0.23 [99% 
CI, 0.11-0.35), speed-processing (0.76 [99% CI, 0.62-0.90), and reasoning training (effect size, 
0.26 [99% CI, 0.17-0.35]) may be able to improve and maintain higher scores within those 
cognitive domains 3-5 years post-training in elderly individuals.13   
Salminen (2016)’s study found that Dual N-Back can significantly improve executive 
functioning post-test scores in the elderly who are cognitively healthy.  Scores may be 
comparable to that of a young adults’ who has not received training (M = 1.64 and M = 2.34, 
respectively), [t (43) = −7.24, p < .001, Cohen’s d = 2.14).14  
Zhang, Y.’s study found that in the setting of WM functional dysconnectivity, single-
back might be capable of recruiting other brain regions to complete working memory tasks.  This 
is supported by the significant correlation that was observed between improved AVLT scores and 
increased levels of activity found in the left ventral lateral prefrontal cortex 
(t = 3.432, P = 0.001, effect size [ES] = 0.793), the inferior parietal lobule 
(t = 2.901, P = 0.006, ES = 0.936), and the right fronto-parietal network (t = 3.115, P = 0.004, 
ES = 1.002), despite them being significantly lower during the 1-back task (P < 0.05, Alphasim 
corrected).15  These findings may be applicable to people with CSVD because both study 
populations share right-frontoparietal network dysconnectivity.  The right-frontoparietal network 
is associated with execution control, attention and working memory.  The study’s findings 
support previous trials that support U-shape compensatory mechanisms, which have been 
reported in AD participants.17 
Salminen, T. (2016)’s study found that Dual N-Back can significantly increase white 
mater integrity in the superior and inferior longitudinal fasciculi (SLF), the inferior fronto-
occipital fasciculus, the forceps minor (FM), and the corticospinal tract in healthy, young adult 




parietal regions; and, the FM is associated with supporting communication between frontal areas.  
We cannot discern if the increase in FA values is due to an increased amount of myelination or 
axon density in the bundle fibers.  The lack of significance between increased FA values and 
improved Dual N-Back performance may be due to the short duration of the study.  Anatomical 
changes, like performance gains, could be dependent on amount of training sessions.  
2.15 Description of studies: Mindfulness Meditation 
Three studies on MMP were identified that examined its effects on anxiety levels, 
synaptic plasticity, and/or cognition.  The studies included were by Hölzel, B.18 Wetherell, J,19 
and Newberg.20  
Hölzel conducted a double-blinded, RCT that assessed whether MMP can alleviate 
anxiety symptoms and induce neuroplastic changes in young adults with anxiety disorders.  The 
study enrolled 29 participants, and the DSM-IV was used by clinicians to confirm the diagnosis.  
The study randomized 15 participants into MBSR and 14 participants into the control group-
stress management education class.  The inclusion criteria limited the study to right-handed 
dominance, little experience with mediation (<10 sessions in one’s life-time), participants who 
could undergo f-MR imaging, and participants who were either not taking SSRI’s or have been on 
a stable dose for at least two months.  The study controlled for age, gender, education level, 
comorbid anxiety diseases, and SSRI’s. 
 Wetherell conducted a single-blinded, RCT that assessed whether MMP can alleviate 
anxiety and improve mild neurocognitive dysfunction in the elderly.  The study enrolled 103 
older adults with anxiety or depressive disorders and subjective cognitive impairment.  
Depression and anxiety disorders were confirmed by clinicians using the DSM-IV.  The study 
randomized 56 participants into the control group-health education class and 47 participants into 
MBSR.  The inclusion criteria limited the study to people who have clinically diagnosable 




Measurement Information System PROMIS test scores), subjective cognitive dysfunction, scores 
less than 10 on the Short-Blessed test, deny psychotic or substance use disorders, and participants 
who were either not taking anxiolytics or have been on a stable dose for greater than one month.  
The study controlled for age, clinical variables, gender, education, medications that can affect 
mood and cognition, cognitive differences at baseline (assessed by the PROMIS scale, Wechsler 
Test of Adult Reading, Digit Span subtest, Grooved Pegboard Test, Memory composite test, and 
Cognitive control composite test), prior experiences with mindfulness or yoga practice, and 
regular use of corticoid steroids.  
Newberg conducted a single-blinded, RCT that assessed whether Kirtan Kriya can 
improve cognitive scores and increase cerebral blood flow (CBF).  The study enrolled 14 
participants with MCI, which was confirmed by NINCDS-ADRD.20  The study randomized 7 
participants into Kirtan Kriya and 7 participants into the control group-music group.  The 
inclusion criteria limited the study to participants who were older than age 60, scored >16 on the 
MMSE, and had no prior experiences with meditation or yoga.  The study controlled for age, 
cognitive outcome measures, and prior experience with meditation or yoga.  However, the study 
did not control for anxiety or other psychiatric diseases or baseline differences in CBF.   
Risk of bias: The effects of the interventions appear to be reliable because the studies 
sampled participants randomly, were blinded, randomized participants to either MBSRB or a 
control group, and ran intention-to-treat analyses.  There were no significant differences across 
groups in age, gender, education level, comorbid anxiety diseases, SSRI’s, or adherence to 
protocol.  SSRI’s typically take about six weeks to reach a steady-state, so both studies controlled 
for this well by excluding participants who have been on an SSRI less than one month.  
Hölzel’s study ensured that the differences observed in BOLD signals between groups 
where not due to baseline differences in brain activity by running a post-hoc analysis (p>0.05).18  
When the study enrolled healthy participants for comparison data, the inclusion criteria controlled 




if they had been recently on any medications that would alter cerebral blood flow.  BAI outcomes 
may be overestimated due to self-reporting biases, and the novelty of MRI imaging could have 
confounded outcomes as well.  Over-estimation of BAI scores appears less likely since Perceived 
Stress Scale scores were not significantly correlated to changes in BOLD signal.18  To avoid over-
estimations, changes in stress could have been quantified by measuring am serum cortisol levels.  
Wetherell’s study had a low percentage of missing data, approximately 1%.19  The study 
showed that the missing data did not significantly affect outcomes by running the Missing Value 
Analysis add-on module (χ2 = 15.7, P = .61).19  The findings may not be applicable to elderly 
with cognitive impairment since the diagnosis of MCI was subjective.  Outcomes on anxiety 
scores could be over-estimates since they were measured by self-reported results, but this is 
unlikely because significant changes in cortisol levels were observed. 
Newberg ran a False Discovery Rate - multiple comparisons to verify that the significant 
changes in cerebral blood flow in the intervention group were accurate.  Also, there were no 
significant differences between groups in adherence to protocol: both groups adhered about 75% 
to protocol.20  Outcomes may be affected however because the study did not control for baseline 
differences in CBF or control for psychiatric diseases.  
Effects of intervention: The results of both studies are applicable to people with anxiety 
because diagnoses were confirmed by the DSM-IV.  
Hölzel’s study found that MMP significantly lowers BAI scores, increases BOLD activity 
in the right pars opercularis, left pars triangularis, and right rostral middle frontal cortex, and 
increases the right amygdala’s functional connectivity with the left rostral middle frontal cortex 
(ρ = − .648, p < .001), the right rostral middle frontal cortex (ρ = − .487, p = .018), and the right 
superior frontal cortex (ρ = − .424, p = .044) (ANOVA group-by-time interaction and Spearman's 
ρ (0.05).18  Therefore, MMP can modify functional connectivity.  MMP’s ability to increase 




the VLPFC during Cognitive Behavioral Therapy and on SSRI’s, which are standards of care in 
anxiety treatment.21  These results are applicable to cognitively, healthy adults.  
Wetherell’s study found that MMP significantly improves memory functioning and 
alleviates anxiety in the elderly with GAD and subjective cognitive impairment (p<0.05).19  The 
study showed that a meaningful relationship exists between cognition and anxiety by finding a 
significant correlation between improvements in anxiety and memory scores ((χ21 =4.5, P = .03), 
along with a significant decrease in cortisol levels in the MMP group (paired t = 3.8, P = .0015).19  
The study did not find significant improvements on executive functioning scores (DSST).  To 
bolster its findings, the study also should have run a regression analysis between anxiety scores 
and cortisol levels and between cognitive scores and cortisol levels.  Measuring cortisol levels is a 
more accurate way to measure stress, and we can further study its effects on increasing amygdala 
activity and suppressing Brain-derived neurotrophic factor (BDNF), a factor that modulates 
neuronal survival and regulates synaptic plasticity.22 
Newberg’s study found that Kirtan Kriya caused significant changes in CBF and 
improvements on the following test measures: Right prefrontal cortex - Trails B task (R = −0.61, 
p = 0.02), left thalamus - Trails B task (R = −0.62, p = 0.02) and, left thalamus - Digit Span Test 
(R = 0.56, p = 0.02).20  Listening to a neutral-stimuli served as a good control because no 
significant changes in outcomes were observed on neuropsychological tests, cerebral blood flow, 
and correlations between test scores and blood flow.  More importantly, the active-control group 
did not affect observed outcomes in the intervention group.  
2.16 Description of studies: Donepezil  
Studies conducted by Chen, X23., Wilkinson, D. 24, and Black, S.25 were included in this 
review. The studies were double-blinded, RCT’s that compared Donepezil to a placebo group.  
Wilkinson and Black enrolled participants with probable MCI-due to VCI, with diagnoses 




which was assessed by using neuropsychological tests.  A score of 1SD below age-adjusted 
normative values on at least one memory and learning test was defined as probable-MCI. There 
are varieties of different tests that can assesses this, but Chen used the Hopkins Verbal Learning 
Test–Revised, Mattis Dementia Rating Scale: Memory subscale, Wechsler Memory Scale–III: 
Logical Memory, and Brief Visuospatial Memory Test–Revised tests.     
Chen’s study examined if Donepezil could enhance cerebral blood flow in MCI-AD 
participants while performing a verbal memory task and HVLT test.  The study enrolled 11 
participants and randomized six participants to the Donepezil group and five participants into the 
placebo group.  The inclusion criteria limited the study to participants with subjective and 
objective measures of MCI and global cognition scores within normal limits (MMSE average 
score was 29).  The study screened for vascular diseases and functional deficits to exclude people 
with cognitive impairments due to probable VCI or dementia from enrolling.  The study 
controlled for age, baseline cognitive test scores, education, and gender.   
Wilkinson and Black conducted similarly designed studies that assessed whether 
Donepezil could improve cognitive scores over a twenty-four-week trial.  Wilkinson enrolled 616 
participants and randomized 193 participants to the placebo group, 208 participants to Donepezil 
5mg/daily group, and 215 participants to Donepezil 10mg/daily group.  The inclusion criteria 
limited the study to participants who met at least one of the NINDS-AIREN criteria, scored 
between 11-25 points on the MMSE, and screened negative for unstable medical conditions and 
psychiatric disorders.  The study controlled for demographic characteristics, clinical variables, 
neuropsychological tests, past cognitive enhancing drug-use, and primary outcomes at baseline.  
Black enrolled 603 participants and randomized 199 participants to the placebo group, 198 
participants to Donepezil 5 mg/daily group, and 206 participants to the Donepezil 10 mg/daily 
group.  Black used the same inclusion criteria and controlled for the same variables as Wilkinson.  
Both studies also measured the same outcomes, which were mean changes between groups on 




and Clinical Dementia Rating-Sum of the Boxes (CDR-SB) tests.  Wilkinson included MMSE 
test scores, while Black did not.  Neither trials used tests that directly measured executive 
functioning.  
Risk of bias: The effects of the interventions appear to be reliable because the studies 
sampled participants randomly, were blinded, and randomized participants to either Donepezil or 
a control group, and ran intention-to-treat analyses.  There were no significant differences across 
groups in age, gender, education, CT scan images, cardiovascular risk factors, and 
neuropsychological tests.  
Chen supported his observations that Donepezil significantly decreased cerebral blood 
flow decline during the verbal memory task by running an analysis to detect for cerebral flow 
differences at baseline (p<0.05).  Selection biases may affect outcomes because MMSE scores of 
26 or 27 are typical cut-off scores with similar educational and socioeconomic backgrounds to 
avoid missing true cases.26 However, participants did need to score 1 SD below normative scores 
in at least 1 cognitive domain.      
Wilkinson and Black’s results are applicable to elderly with VCI because the study 
confirmed the diagnosis with the NINDS-AIREN criteria.  The study’s sample included (33%) of 
participants with identified subcortical strokes, so the studies’ results may be applicable to CSVD 
as well.  Executive functioning deficits are common though in VCI and Donepezil’s effects on 
this measure are unknown because it was not directly assessed.  
Effects of intervention: Chen’s study found that Donepezil caused less cerebral blood 
flow decline in the left temporal by 1.51 ml/min/100g and in the left frontal tissue by 1.69 
ml/min/100g in comparison to the control group (p<0.05).23 There were no significant differences 
between group scores on these tasks. Therefore, Elderly who have been diagnosed with MCI-due 
to AD for six months or less may experience less cerebral decline while performing some 
memory tasks and it may improve memory performance scores.  People who do not take 




Wilkinson’s study found that elderly persons, who have been diagnosed with mild VCI 
for 24 weeks or less, might experience small improvements on global cognitive functioning 
assessments on 5 or 10mg of Donepezil in comparison to people who do not take the drug.  
Black observed similar smaller effect sizes.  At 24 weeks, Black’s study found significant 
improvements in baseline ADAS-cog scores and ADFACS Scores in the Donepezil 5 mg/d group 
(ADAS-cog effect size = −1.90, p = 0.001; ADFACS effect size = −1.31, p = 0.02) and Donepezil 
10 mg/d group (ADAS-cog effect size= −2.33, p<0.001; ADFACS effect size = −1.31, p=0.02).25 
Significant improvements in baseline CIBIC-Plus scores were only observed in the donepezil 5 
mg/d group (p=0.014), while significant improvements in baseline CDR-SB scores were only 
observed in the donepezil 10 mg/d group (p=0.007).25 Both studies showed that Donepezil was 
well tolerated by observing no significant differences between groups in adverse side effects and 
withdrawal rates (p>0.05).24,25    
2.17 Description of studies: Multidomain Intervention Study: Physical Exercise  
Ngandu’s multi-domain intervention was included into this review because it was a 
double-blinded RCT that enrolled healthy-to-MCI elderly who had similar clinical traits that are 
found in CSVD, like HTN and diabetes.  MCI was determined by Consortium to Establish a 
Registry for Alzheimer's Disease (CERAD) neuropsychological battery test scores, which 
assessed memory and recall.  
The study assessed if diet, exercise, cognitive training, and metabolic control could 
synergistically slow cognitive decline.  Cognitive decline was measured by mean change in 
baseline NTB (z score) scores over two-years.  Secondary outcomes measured changes in 
executive functioning, memory, and speed processing scores, and the intervention’s effects on 
improving risk of cognitive decline were assessed.  
 The RCT enrolled 1,190 elderly participants and randomized 591 participants to the 




education.  The inclusion criteria limited the study to participants who were between the ages 60–
77 years old, scored a 6 or higher on CAIDE (Cardiovascular Risk Factors, Aging and Dementia) 
Dementia Risk Score, and scored 1SD below normative scores on either the MMSE (<26 points), 
word-recall list task (<75%), or word-list memory task (19 points).27  The study did not exclude 
cognitive impairment possibly due to CSVD. The study controlled for age, education, MMSE 
scores, vascular and lifestyle risk factors, and cognitive differences at baseline (NTB total score, 
executive functioning, processing speed, and memory).27 
Risk of bias: The effects of the intervention appear to be reliable because participants 
were randomly sampled, blinded, and randomized.  There were no significant differences across 
groups in age, education, vascular and lifestyle risk factors, and cognitive scores at baseline.  The 
drop-out rate was minimum, with only 4% from the multidomain group and 7% from the control 
group.27  Missing data was handled by performing modified intention-to-treat analyses.  Missing 
results did not affect significance, as determined by the re-calculation with intention-to-treat 
analysis.27  Outcomes may have been affected by information biases since adherence to protocol 
was only self-reported, and practice effects may have confounded outcomes.  
Effects of intervention: The study observed a 25% risk of cognitive decline in NTB z-
scores over two years in the control group.  The multidomain approach also improved speed 
processing and executive functioning scores (p=0.039) in the intervention group.27  The study did 
not compare the different interventions to determine if one was significantly better than another 
was.  There is a debate as to whether physical exercise versus cerebral blood flow helps 
promote cognitive improvement.  One review observed moderate gains in memory in elderly 
participants without MCI after acute exercise, but the benefits were lost after 14 months.28  The 
observed gains may be due to physical exercise stimulating the release of BDNF, nerve growth 
factor (NGF), and insulin-like growth factor (IGF-1).29 MMP is another intervention that has been 





2.18 Review on Instruments of Measurement 
2.19 Description of studies: Alzheimer's Disease Neuroimaging Initiative-Executive Functioning 
(ADNI-EF) test 
The ADNI-EF test is a composite of seven, executive functioning tests.  These tests 
include Category fluency: Animals and Vegetables, Digit Span Backwards, WAIS-R Digit 
Symbol Substitution (DSST), Clock Drawing, and Trails B–Trails A.30  These seven tests were 
included into the Vascular Cognitive Impairment Harmonization Standards by the National 
Institute for Neurological Disorders and Stroke (NINDS) and the Canadian Stroke Network 
(CSN).31  These standards were created to help identify VCI patients for future studies. In the 
VCI Harmonization standards, Clock Drawing and Trails-B are considered supplementary test.31  
 The composite ADNI-EF has only been studied in one trial that began in 2003 and was 
supported by the National Institute on Aging (NIA), the National Institute of Biomedical Imaging 
and Bioengineering (NIBIB), the Food and Drug Administration (FDA), and private and non-
private pharmaceutical companies.30  The ADNI-EF study was created to determine if MRI and 
PET imaging, biological markers, and neuropsychological assessments could detect the 
progression of MCI to AD.  The three-year study examined this by trying to determine if a 
significant correlation existed between ADNI-EF z-scores and cortical changes on MRI, amyloid 
β1-42, total tau, and phosphorylated tau181-P, levels in CSF, and MCI-AD conversion rates.30  The 
study sampled participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
database and recruited 229 participants with normal cognition (Age 76.0 ± 5.0, N= 229), 397 
participants with MCI (n= 390, 74.9 ± 7.5), and 193 participants with AD (n=181, Age= 
75.7 ± 7.4).30  The inclusion criteria limited the study to either elderly with healthy cognition, 
MCI-due to AD, or AD.  The study controlled for age, education, sex, and the presence of one or 
more APOE ε4 alleles.30  
Risk of bias: The ADNI-EF model appears to be reliable because significance could 




affect outcomes.30 The study found statistical significance on its three validation markers, even 
with a reliability curve ranging from 0.85 to 0.75 (p<0.05).30  MR-imaging was one if its 
validation markers and ADNI-EF z-scores were significantly correlated to frontal lobe cortical 
thickness (p<0.05).30  The model may have failed to reach higher reliability because the tests 
were administered to a study population that is distinctively known to have impairments in 
declarative episodic memory.32  The study did not compare the seven tests to determine if one 
was significantly better than another, and there is no guarantee that these tests truly measure 
frontal lobe executive performance.  The significant correlation found between ADNI-EF z-
scores and frontal lobe cortical thickness helps disprove this.  In addition, normal distribution 
calculations are more reliable than skewed calculations, which must be calculated on some 
neuropsychological tests.  
Effects of intervention: ADNI-EF z-scores were significantly correlated with MCI-AD 
conversion rates, MRI images from selected brain regions, and levels of amyloid β1-42, total tau, 
and phosphorylated tau181P in CSF levels.30 Though VCI participants were not enrolled in the 
study, the ADNI-EF composite test may be a useful measurement to assess an intervention’s 
effect on improving executive dysfunction.   
2.20 Description of studies: Connectome-based predictive modeling (CPM) 
CPM is a relatively new technique that receives inputs of connectivity and behavioral 
performance data and outputs high and low functional performance networks that are correlated 
to high and low behavioral scores.33  The significant correlation between functional 
connectivity and behavioral performance enables the model to predict behavioral outcomes in 
that individual subject. The CPM networks can then be trained on new data sets and make 
accurate behavioral predictions in new cohorts.  CSVD’s white matter damage leads to 




these dysconnectivity’s and can provide a gestalt measure of executive functioning abilities and 
executive dysfunctions in CSVD.   
CPM’s methods are still being refined as we learn more about brain networks and 
improve computational methods to create more accurate predictor models.  The NIH is funding 
the Human Connectome Project and has provided open source sharing to allow researchers 
assess to templates and protocols to conduct experiments in order to add meaningful data to the 
brain mapping project.34  A part of the human connectome project is to identify and learn how 
functional networks produce certain behaviors. Behavioral templates that are currently offered 
by the NIH are rest, emotion, gambling, language, motor, relational, social, and working 
memory.34,35  Executive functioning is not a behavioral task offered.  The ADNI-EF can be 
completed under MR-imaging and provide meaningful data about functional connectivity in 
executive functioning.  We will not discuss the CPM protocol because templates are provided 
by the NIH34, Nature has published in detail how to perform the CPM computations in 
MATLAB33, and an architype of CPM was developed here at Yale in the study of functional 
connectivity in attention and Attention Deficit and Hyperactivity Disorder (ADHD).36  
Risk of bias: CPM’S outcomes may be affected by the statistical test chosen to 
calculate the connectivity matrix edges.  The Nature protocol states that edge calculations can 
be made with either Pearson's correlation, Spearman's correlation, or robust regressions. 33  The 
ADNI-EF computed its model with robust regressions and calculated a reliability between 
0.85 to 0.75.30  The ADHD study computed its edges with “Spearman-Brown-corrected split-
half correlation” and calculated a reliability of 0.975, which is considered excellent.36  Either 
regression model would still overestimate or underestimate performances, and therefore, CPM 
provides good relative data.  The amount of imaging data from participants may also affect 
outcomes: the ADHD study enrolled 25 individuals, and the ADNI-EF study’s data comes 
from 800 participants.  The imaging modality of choice is 3T or 7T magnetic resonance 




2.21 Description of studies: Diffusion tensor (DTI) and dynamic susceptibility contrast (DSC)  
The MRI images that will be used in CPM will come from DTI - DSC sequence 
protocols.  In accordance with Standards for Reporting Vascular Changes on Neuroimaging 
(STRIVE)37 and Fisher criteria,38 lacunar infarcts can be visualized on T1-, T2-FLAIR, and T2-
weighted sequences on MRI. Functional connectivity is assessed with brain-blood-oxygenation-
level-dependent (BOLD) f-MRI.  
Only one studied was identified that visualized leukoaraiosis with 3T BOLD and DTI 
MR-imaging (Sam, K.).39  The study tried to assess whether impaired cerebrovascular reactivity 
(CVR) is significantly correlated with white mater tissue integrity and evaluated this by using 
diffusion and perfusion MR-imaging.  The participants were conveniently sampled and 75 
patients with moderate to severe leukoaraiosis were enrolled into the study.  The inclusion criteria 
limited the study to participants who had cortical infarcts or white mater lesions less than two 
centimeters, a Fazekas score greater than two, older than fifty-years of age, hemodynamic 
instability less than 70%, and no subcortical infarcts within three months of enrollment.  
Participants whose BOLD images had motion artifacts were excluded from the study.  
The study controlled for poor imaging quality, such as imaging spatial confounds. 39  
Risk of bias: The study’s outcomes may be compromised because imaging could not 
discern if there were other factors besides ischemia that were causing WMH.  The study did 
control for head motion artifact and imaging spatial confounds.39  Selection bias of convenience 
sampling may also affect outcomes.  
Effects of intervention: The study observed that T2-weighted images are less likely to 





2.22 Description of studies: Neuropsychological and behavioral tests  
Please refer to the appendix for more information on the neuropsychological and behavioral 
tests that are used in this study.   
 
2.23 Effects of interventions on primary and secondary outcomes 
 
Non-pharmacological effect sizes on primary and secondary outcomes that are used in 
this study were found in a systematic review on cognitive training.  The systematic review was 
called “Cognitive training and cognitive rehabilitation for persons with mild to moderate 
dementia of the Alzheimer's or vascular type: a review.”  Cognitive training was observed to have 
a large effect of 7.47 (-14.19, 29.14) on DSST scores in a sample of 153 participants;8 a large 
effect of 14.53 (-9.35, 38.41) on Trail-B Test scores in a sample of 77 participants;8 and, a large 
effect of 25.26 (-76.70, 26.19) on Trail-A Test scores in a sample of 76 participants.8 On 
secondary outcomes, cognitive training had a poor effect size of -0.94 (-3.67, 1.79) on BOLD 
activity in a sample of 35 participants;8 and, a poor effect size of 0.03 (-0.34, 0.41) on anxiety 
scores in a sample of 114 participants.8  Observing similar effect sizes from cognitive training are 
unknown because these measures were not obtained in CSVD participants.  
 
2.24 Conclusion 
2.25 Summary of main results 
The aim of this review was to evaluate the current evidence regarding the efficacy of 
adaptive cognitive training and MMP on improving executive functioning for people with MCI-
CSVD.  We included nine studies of adaptive cognitive training and MMP into this literature 
analysis, along with two studies on Donepezil and one multi-domain study.  These interventions’ 
effects on executive functioning could not be analyzed because of the variability in outcome 




training and MMP to have the potential to generate small-to-medium effects on executive 
functioning.   
2.26 Applicability of evidence  
Cognitive training and MMP have not yet been studied in MCI-CSVD, so the 
interventions’ effects may or may not be reproduced in this study population.  Ngandu27 and 
Zhang’s15 studies support cognitive training to promote some cognitive improvements in the 
elderly with cardiovascular risk factors that would predispose them to lacunar infarcts.40  The 
systematic review on cognitive training in participants with AD or VaD supported small 
improvements on some executive functioning tests.8  
This review may have missed significant effects because of the limited number of 
relevant RCT’s available, the varying terminology that references this study population and the 
interventions studied, and because of the included studies methodological limitations.  
Limitations in study design include duration of intervention, active versus no-contact groups, and 
the use of neuropsychological tests to assess functional performance.  Jaeggi found that the 
number of treatment doses is directly correlated to behavioral performance gains.12  The standard 
number of doses to reproduce effects remains unknown, as it would be individualized for 
participants. The superiority of active-control groups over no-contact groups remains unknown.  
Participants have received cognitive gains from single-back, so this may serve as a poor control 
group, whereas listening to a neutral stimulus may act as a better placebo.  Neuropsychological 
tests can confound results by Hawthorne and practice effects.  The studies included in this review 
prevented against Hawthorne affects by administering many versions of the same test.  Many 
studies administer multiple tests because one neuropsychological test does not accurately assess 
functional performance.  A better way to measure functional performance is to calculate the 
correlation between neuropsychological test scores and micro-structural or functional changes on 




2.27 Disagreements with other studies 
The current “Grade A” recommendation in the treatment of MCI is to discuss with 
patients the options of cholinesterase inhibitors.7  The evidence does not support the 
administration of Donepezil to be a Grade A practice.  The studies failed to assess the 
interventions effects on the disease’s most common deficit, executive functioning.  Instead, both 
studies administered tests that are commonly used in AD studies.  Furthermore, when Donepezil 
was studied in the elderly with MCI-due to AD, the placebo group maintained their memory 
performance scores over the six-month period and no significant differences were observed 
between the two groups.  
2.28 Implications for research  
The high-quality studies offered in this review support combined MMP and adaptive 
cognitive training (Dual N-Back)’s beneficial effects on cognition.  However, this cannot be 
confirmed until a well-designed, single-blinded RCT is conducted in this population.  
Furthermore, the use of CPM and imaging will allow us to measure these interventions’ 
effectiveness on functional and executive functioning performance.  The literature review 
supports the need for this current study to be conducted.  
2.29 Key Terms  
 
VaD: vascular dementia; Subcortical ischemic vascular dementia; Lacunar infarction; Vascular 
factor; Cerebrovascular disease; MCI: mild cognitive impairment; AD: Alzheimer's disease; 
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fMRI: functional magnetic resonance imaging; CDSR: Cochrane Database of Systematic 
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Chapter 3 - Study Methods 
 
3.1 Study Design  
 
The present study will be implemented as a two-arm superiority, single-blinded 
randomized control trial (RCT) that will randomize and allocate participants with MCI-CSVD 
into either the control group who will engage in placebo (solitaire and music listening) per day or 
into the experimental group to receive mindfulness meditation and Dual N-Back to assess its 
efficacy in slowing the progression of executive dysfunction.  
3.2 Synopsis 
 
- Ninety-seven people will be recruited and consented after screening for eligibility.  We will be 
screening for vascular cognitive impairment due to small vessel disease phenotype rather than 
large vessel disease.  
 
- Subjects with anxiety, depression and alternative diagnoses will be ruled out.  
- They will be randomized to a low intensity (placebo group) and high intensity intervention 
group. 
 
- The low intensity group includes playing solitaire for half an hour and listening to music for 
another 30 minutes – daily.  
 
- The high intensity intervention group consists of playing Dual N-Back for 30 minutes and 
meditating for 30 minutes – daily.  There are group sessions three times per week which are 
required for the first two weeks of enrollment but voluntary from then on.  
 
- Each subject will be in the study for 12 weeks after which a voluntary subset may decide to 
continue the routine for future studies and measurements. 
 
- Imaging and neuropsychological testing is performed at baseline and at the end of the 12 weeks.  
- Primary endpoint is changes in Alzheimer's Disease Neuroimaging Initiative (ADNI)- Executive 
Function (ADNI-EF) composite measure.  Secondary endpoints include changes in 
neuropsychological scores and changes in connectivity, especially in the sub-graph of the 




Our sample size for this study is 74 participants.  However, we will enroll 97 participants 
because we expect a 30% drop-out rate based off other MCI studies that involved physical 




power analysis computed that 74 participants would be needed to determine a significant difference 
between two groups, with the study set at a 5% significance level, powered at 80%, and effect size 
F of 0.25. Please refer to the appendix to view sample calculation.  
The source population is elderly people with VCI due to CSVD without mood disorders.  
Our sources of referral will include Yale Memory Clinic, Yale Stroke Center, Adler Geriatrics 
Centre, and Yale Program on Aging.  We will ask physicians to participate and to help provide 
referrals.  For those physicians who agree to participate, we can help them identify appropriate 
referrals to our study by asking Epic’s Joint Data Analytics Team to cross reference VCI, white 
matter disease, lacunar infarct, vascular dementia and CSVD with participating physicians.  We 
will post an advertisement of our study on the Help Us Discover Now site.  The advertisement will 
ask for elderly people with MCI due to cardiovascular risk factors, like stroke or DM, to participate 
in a study that is trying to slow the progression of cognitive decline.  Identified individuals will 
present to Church Street Research Unit for eligibility screening.  
 
3.4 Study population  
 
We will be enrolling both men and women equally into our study, and we expect to enroll 
ethnicities that are more prevalent in the state of CT, which are Caucasians, African-Americans, 
and Hispanics.  Participants must be English-speaking.  
3.5 Inclusion Criteria 
1) Participants need to be between the ages 50 to 89 years-old with MCI due to vascular 
pathology according to VASCOG criteria.2  
 
2) The cognitive deficit should be subcortical, more than cortical, suggesting small rather than 
large vessel disease pathology.  
 
3) Study partner should confirm cognitive decline. 
 
4) Relative novice to cognitive training and meditation. 
 




3.6 Exclusion Criteria 
1) Drug or alcohol substance misuse 
 
2) Use of medications that affect cognition within 30 days of the study 
 
3) Exclude patients with depression and anxiety 
 
4) Major neuropsychiatric conditions such as Parkinson’s disease, Huntington’s disease, 
multiple sclerosis, tumor, epilepsy, or psychiatric diseases like schizophrenia  
 
5) Consumption of greater than five alcoholic drinks per week within the last 30 days  
 
6) Participants’ whose past medical history is pertinent for Chronic Obstructive Pulmonary 
Disease, active infection, cancer, autoimmune diseases, or serious systemic illnesses, such as 
hepatic, renal, or heart failure 
 
7) Participants with visual, auditory, or other physical impairments that would interfere with 
completing the study’s procedures and interventions: 
 
a) Participants who are physically unable to partake in the interventions mindful meditation 
and Dual N-Back 
b) Participants who have relative or absolute contraindications for undergoing magnetic 
resonance imaging (MRI), which includes claustrophobia and metal pieces implanted 
inside the body 
 
8) Education less than 9 years 
 
3.7 Screening Procedure 
 
1) The subject should meet the criteria for VCI, according to the VASCOG criteria.2  These 
include: 
 
a) Subjectively: Participants should state that they now require greater effort to complete 
multiple tasks and feel fatigued and/or struggle with word finding and memory retrieval, 
and/or bladder control.  Presence of vascular risk factors will also support a diagnosis of 
VCI.  
 
b) Objectively:  
i) Physical Exam: Participants must present with at least one of the following clinical 
features suggestive of CSVD: gait apraxia, urinary urgency, affective dysregulation 
that includes apathy, or pseudobulbar affect.3  
ii) Imaging at Magnetic Resonance Research Center (MRRC): Participants’ MRI imaging 
must be positive for lacunar-strategic infarcts.  Lacunar infarcts will be identified in 
accordance with the Standards for Reporting Vascular Changes on Neuroimaging 
(STRIVE)4 and Fisher criteria.5 Lacunar infarcts will be visually inspected on T1-, T2-
FLAIR, and T2-weighted images (WI) on MRI scans.5 To be classified as a lacunar 
infarct, the lesion must be approximately 3-15 mm in diameter and accepted locations 




corpus callosum, fornix, lentiform nucleus, internal capsule, centrum semiovale, and 
brainstem.6,4 Lacunar infarcts will be identified as round or ovoid-shaped rims of 
increased signal relative to white matter on T2WI and T2-FLAIR images or decreased 
attenuation on T1WI.5  Accepted lesion severity will be a Fazekas score of ≥2.7  Images 
must be absent for cortical and watershed infarcts, hemorrhages, hydrocephalus, and 
white matter lesions caused by non-vascular causes.3 Participants’ must have a 
Scheltens atrophy score of zero in the hippocampus and entorhinal cortex.1  
 
2) A MOCA score of less than 23 and more than 19 will be used to recruit participants.8  They 
should lose at least one point on Letter fluency (F, A and S)9 or vigilance A10. 
 
3) Participants’ surrogates must confirm his or her MCI by completing the Informant 
Questionnaire for Cognitive Decline in the Elderly.3  With a threshold score of 65, the test has 
a sensitivity of 66.1% and specificity of 59.8%.11   
 
4) Participants must screen negative for depression: Participants must score less than 16 on the 
Centre for Epidemiologic Studies-Depression Scale (CES-D).12 The test has a specificity of 
90%, sensitivity of 86%, and a positive predictive value of 80 with a cut-off score of 16.12   
 
5) Participants must screen negative for anxiety, which will be measured by the Beck Anxiety 
Inventory (BAI) test.  A score less than nine will be accepted because it indicates “mild 
anxiety.”13  BAI is a strong, valid, and reliable test in psychiatric populations, but it may not 
always be able to discriminate between somatic factors and true anxiety.13 However, the BAI 
is superior to the STAI in discriminating between somatic anxiety and trait anxiety and 
separating patients with a current anxiety disorder from patients without the disorder.14  
 
Please refer to the appendix to view baseline characteristics of participants.  
 
3.8 Baseline and follow-up testing 
  
Baseline testing will include tests not performed during the screening.  Both baseline and 
screening tests will be repeated during the follow-up.  The tests will be scored and normed 
according to age and education of the subjects.15  The tests include Category fluency (Animal, 
Fruit, Vegetable)16, Digit span16, Digit symbol (DSST)3,16,17, Trails A and Trails B16, Boston 
Naming Test (BNT)3,18, Neuropsychiatric Inventory (NPI)3,19, Letter fluency (F, A and S)9, Rey 
Auditory Verbal Learning Test20 (RAVLT), Logical memory21, and Functional Activities 
Questionnaire (FAQ).22  Please see the appendix section for more information on these tests.  The 
BNT, RAVLT, Logical memory, and Vigilance A test instruction and scoring manuals are not 




3.9 Randomization and Blinding 
 
Once patients have passed screening, they will be assigned to placebo or intervention arms by 
a pseudorandom number generator.  The investigators will be blinded to the intervention and 
placebo arms.  The subjects will be told that we are comparing two different types of non-
pharmacological interventions.  
 
3.10 Interventions 
3.11 Control Group: Low-Intensity Intervention  
Participants who are randomized and allocated to the low-intensity intervention are offered tuition 
for playing solitaire and listening to selected music for a total of one-hour per day.  Participants 
will be expected to play 30 minutes of solitaire followed by 30 minutes of listening to relaxation 
music for 12 weeks.  These activities will be placed on a server onto which they will need to log 
onto to have their compliance recorded.  They will be paid 5 dollars per session completed.  For 
those with less than 80% compliance on a weekly basis, one warning will be given, followed by 
dys-enrollment from the study if low compliance continues. 
3.12 High-Intensity Intervention  
Participants enrolled in the combined mindfulness meditation (MM) and Dual N-Back will 
come to clinic 3 times a week to play 30 minutes of Dual N-Back, followed by 30 minutes of 
meditation.  Participants will be expected to follow this same protocol on days that they are 
not at clinic.  These activities will be placed on a server onto which they will need to log onto to 
have their compliance recorded.  For those with less than 80% compliance on a weekly basis, one 
warning will be given, followed by dys-enrollment from the study if low compliance continues.  
Groups session will be mandatory during the first two weeks of the study, but after that, the 




3.13 Cognitive Training  
Participants will play the computerized adaptive training program, Dual N-Back, on 
their devices.  The Dual N-Back is adaptive as to ensure adequate intensity of training in these 
individuals.  The objective is to increase the length of time, or number of n-trials, one can 
correctly recall information from.  Participants will be presented every three-seconds with two 
series of stimuli, single letters and images.23  Participants will need to determine if the presented 
number and image location match what was presented to him or her two trials ago. Participants 
will respond by pressing or not pressing a designated letter on a keyboard.  
The game changes in level of task-difficulty based on performance.  As performance 
improves, the number of trials participants must recall stimuli from will increase.  If performance 
worsens, the number of trials will either decrease or stay at two.  At the beginning of the study, all 
participants will start with having to remember stimuli from two trials ago, but the training adapts 
to participants’ own cognitive abilities and is personalized across participants.  Participants’ 
results will be automatically uploaded into a computer to be analyzed later by an outcome 
assessor.  We will keep track of n-trials for each participant. 
For participants to be included into data analysis, they must complete 80% of the total 
Dual N-Back sessions.  Adherence is measured by attendance and total number of uploaded 
results.  We will record the number of trails completed and task-difficulty level for each 
participant.  
3.14 Mindfulness Meditation  
Participants will need to practice MM every day for thirty-minutes either at clinic or at 
home.  Group sessions will be offered three times per week.  On days participants are not at 
clinic, they will need to log onto a server at the beginning and end of each MM session to clock in 




Class sessions will include breath-awareness, body-scan, and gentle Hatha yoga.  Breath 
awareness exercises will ask participants to be cognizant of their breathing and to expand their 
awareness onto other body sensations, thoughts, and emotions.24  Participants will then be asked to 
nonjudgmentally accept those sensations and return their mental focus onto their breath.24  Body 
scans will ask participants to scan their body’s from head-to-toe to explore for  different types of 
sensations, such as pressure or tightness, and then to intentionally release that focus before shifting 
onto the next body part.24  Hatha yoga exercises will require participants to gently stretch and slowly 
move through different poses while focusing on present experiences.24   
For participants to be included into the data analysis, they must complete 80% of the total 
sessions.  Adherence is measured by attendance and total number of logged in sessions on the 
server.  
 
3.15 Imaging Protocol 
 
We will measure alterations in white matter microstructure by using Diffusion Tensor 
Imaging (DTI), so called structural connectivity, and we will measure functional connectivity by 
using c-fMRI.  The c-fMRI images will be obtained while positive-tasks are being performed 
by participants in the scanner.  The positive task will be a succession of the Category Fluency— 
Animals, Category Fluency- Vegetables, WAIS-R Digit Symbol, Digit Span Backwards, Trails A, 
and Trail B tests.  For each participant, connectivity matrices will be made during each of these 
subtasks and averaged over the entire scan periods.  Yale MRRC already standardizes the nodes 
and regions of interest, and we will use these in our study.  The aggregate subject connectivity 
matrices are then used to look at correlations between connection strengths and test scores.  This 
can also be referred to as an edge and only significant edges will be kept (p<0.01).  This analysis 
can be run for both high-performance and low-performance.  We will then examine if the sum of 
the connection strengths in the high-performance network can predict ADNI-EF parameters.  We 




determine if it improves our model’s prediction power.  We will repeat these steps for each of the 
tests that composite the ADNI-EF.  The same analysis will be performed using DTI, however it is 
difficult to think of a mechanism whereby structural connectivity changes in a short period in 
response to training.  Please see the appendix section.  
We will then see if changes in ADNI-EF, after cognitive training, are reflected in 
connection strength in the high-performance network.  If so, this would provide one of the most 
convincing evidence for neuroplastic changes in response to cognitive training in the experimental 
literature.  
3.16 Study Variables and Measures 
 
The composite ADNI-EF scores will be calculated for each intervention group in the same 
manner it was computed in the study, “A composite score for executive functioning, validated in 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive 
impairment.”16 Once composite ADNI-EF scores are computed, we will then calculate a z score 
for each intervention group by using the below equation.  The Z score will be standardized to the 
baseline mean and SD, with higher scores suggesting better performance.  
Z= raw score – mean of the sample / standard deviation (SD) of the sample. 
We will use these standard scores to compute our own prediction interval calculations.  Interval 
calculations will be computed by using the following standardized, mathematical equation.  
 
P (Lower end-point of the mean population – z-score*SD) - mean population / SD < Z 










3.17 Statistical Analysis  
3.18 Primary Outcome 
To determine a significant difference between groups (group × time interaction) at the 
end of the study, we will run an ANOVA Repeated Measures, Between Factors.  Significance 
will be set to p < 0.05. Analysis will follow per protocol.  The independent variables are the 
interventions, Low - intensity versus High - intensity interventions, and the dependent variable is 
ADNI-EF z-score.  The confounding variables that will be controlled for are for BAI scores, age 
and sex.16   
3.19 Secondary Outcomes 
Modifications in cerebral blood flow and structural connectivity.  To assess whether 
both groups experienced significant changes in cerebral perfusion and structural connectivity 
over 12 weeks, we will run a Two-Way Mixed-Model ANOVA (within-subjects’ factor: time; 
between subjects’ factor: treatment).  Significance will be set to p < 0.05. If significance is 
found, we will run a post hoc test. 
Effects on cognitive domains.  To test the interventions’ effect on different cognitive 
areas, we will calculate mean change in scores from baseline to twelve weeks post-treatment 
initiation within-groups.  To determine significance between groups, we will run a repeated 
measures ANOVA.  
 
3.20 Missing Data 
 
Continuation in the study requires more than 80 % compliance with the 
interventions.  As with problems with missing data on neuropsychological testing, if the 
constituents of ADNI-EF are missing from the data, the subject will be excluded from the 





3.21 Ethical Parameters 
3.22 Subject Protection and Confidentiality 
The study design will be carried out in accordance with the guidelines set by Yale’s 
Human Investigation Committee (HIC) and Institutional Review Board (IRB) by adhering to their 
regulations written in Procedures 100 PR1.25  Our study will also follow the guidelines written 
in Policy 340: Participation of Individuals with Impaired Consent Capacity.26  Participants must 
have capacity to enroll into the study and also designate a study partner for collateral information.  
Participants will need to sign the consent forms during the visit for eligibility screening.  Lastly, 
our protocol will include adequate provisions for monitoring collected data and ensuring privacy 
and confidentiality so that our study is HIPPA compliant.  Consent forms and study protocol will 
be submitted to the Yale New Haven Research Unit Committee so that we may receive documented 
approval and begin our study.  
Experimental studies may involve potential and unforeseeable risks that include physical 
harm or loss of confidentially.  To mitigate potential harm, we have created a list of potential risks 
and corresponding action plans to address them should they occur.  This list will be provided to 
participants in the consent form.  Please refer to the consent forms in the addendum.  Below, we 
included our minimal risk data safety monitoring plan.  
3.23 Minimal Risk Data and Safety Monitoring Plan 
The Principal Investigator (PI) will be responsible for monitoring and protecting the data 
under the laws of HIPPA, assuring that those involved in the study are adhering to the study 
protocol that is provided to the IRB, and conducting, at minimum, monthly safety reviews.  During 
these review processes, the PI will assess whether the study’s protocol should continue unchanged, 
require amendments, or close to enrollment.  Changes in protocol will only be made in the interests 




and the IRB.  The PI and the IRB will have the authority to stop or suspend the study or require 
modifications. 
Subjects’ overall risk for adverse events in this study are low, as exemplified by the 
potential risks and associated action plans provided in the participants’ consent forms.  
Interventions and methods will only be carried out by certified professionals who have completed 
the training module, “Ethics on Human Research.”  Medical tests and imaging will be conducted 
by licensed staff members from the hospital; diagnoses will be made by certified neurologists; 
outcome data will be collected and analyzed by experienced research assistants; meditation will be 
taught by a certified instructor; neuropsychological tests will be evaluated by a psychiatrist or 
neurologist.; and, the principal investigator, Dr. Salardini, is an appropriately trained medical 
professional who has been trained in neuropsychiatry, neurology, and internal medicine.  
In terms of risks unrelated to health, there is low-risk associated with collection and 
attainment of subjects’ protected health information.  We will be requesting for a signed consent 
waiver during the recruitment process because this research could not be conducted without access 
to and use of the protected health information.  However, we ensure that the collected protected 
health information will not involve increased risk to patient’s privacy; adequate plans will prevent 
against the improper use and disclosure of identifying information; and, the identifying information 
will be shredded and destroyed at the earliest opportunity, unless such retention is required by law 
in the interests of patient safety.  Lawful authorities will include members overseeing the research, 
such as the IRB.  
To protect confidentiality, methods to protect data will include the use of password 
protected programs, encrypted software, use of secured servers, along with storing papers in 
locked-filing cabinets.  We will also separate personal identifying information and results, and 
results will be published as group data to avoid using identifying information.  Our study will 
adhere to these provisions to avoid the potential harm that could occur should confidentiality be 




harmful consequences that can occur in the setting of a stolen identity.  In the event of illegal 
disclosure, the event will be documented in the “accounting for disclosures log,” and then 
forwarded to the Deputy HIPAA Privacy Officer.  Participants will be subsequently made aware of 
the disclosure. 
Additional safety measures will be included in this study because elderly with MCI 
impairments are a vulnerable population.  Security measurements will require participants to 
identify a study partner who will be willing to provide additional help with participant participation 
and accompany participants to each drop-off session and to all procedures.  Participants must have 
capacity to enroll in this study, which will be assessed by a medical provider.  We will submit a 
protocol application to the IRB, along with our signatures attesting to the protection of health 
information, and the required HIPPA Authorization forms that participants must sign to participate 
in the study. 
3.24 Monetary compensation 
Subjects will receive $5 per session and can receive a total compensation of $420 upon 
completing the 84 sessions.  They will receive a further $100 for completing both baseline and 
follow-up testing, which includes MRIs and neuropsychological testing.  These are nominal fees 
and not coercive, they merely introduce a form of token economy to increase compliance.  
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Chapter 4 – Conclusion 
 
4.1 Rationale 
4.2 Choice of condition to treat 
a) As we discussed in detail within the introduction, the brain has different kinds and degrees 
of neuroplasticity depending on the localization and age of subjects.  The best examples of 
neuroplasticity which appear to be present lifelong, or at least into old age, seem to pertain 
to the frontal-subcortical circuitry which connect the frontal lobes with the basal ganglia, 
and through the basal ganglia’s connections to the thalamus, to the rest of the brain.  The 
executive and cognitive control role of the frontal-subcortical circuitry means that 
dysfunction in these areas have a disproportionate effect on overall cognitive functioning.  
b) Additionally, we argued that evidence shows that the frontal-subcortical circuitry is 
particularly vulnerable to the effect of CSVD.   
c) It follows from a and b that a mechanism that might engage neuroplasticity may have the 
opportunity to treat some of the executive dysfunction seen in CSVD.  
4.3 The choice of intervention 
a) We also reviewed how Dual N-Back has some of the best track records suggesting 
effects on neuroplasticity of the brain.  Some of our choices regarding this modality 
included: 
 
a. Using a single modality to reach enough intensity and repetition to cause plastic 
changes, as well as avoiding interference.   
b. We use a relatively high dose of intervention, which is at the limits of compliance 
from our clinical experience for the same purpose.  
c. The period of intervention is 12 weeks after which there is enough repetitions in 
the task for it to become habitual.   
 
b) We reviewed the effects of mindfulness meditation and how it suppresses the counter-





1) Our primary hypothesis is that the high-intensive intervention in the form of Dual N-
Back training and mindfulness meditation will have a differential effect on executive 
functioning in subjects with CSVD.   
 
2) Exploratory hypothesis 1: We hypothesize that improved executive function will 
positively affect other cognitive domains.  
 
3) Exploratory hypothesis 2: Changes in executive function may be correlated with 







4.5 Specific Aims: 
 
1) To demonstrate less negative change in ADNI-EF score during follow-up compared to 
baseline, in the high-intensive intervention group compared to non-intensive 
intervention group. 
 
a) Subjects in the high-intensive intervention group will receive instructions to 
play Dual N-Back daily (30-minutes) and to meditate (30-minutes) for 12 
weeks, during which they have an option of performing this task in supervised 
groups three times per week.   
b) Subjects in the non-intensive arm will also receive instructions to play solitaire 
daily (30-minutes) and to listen to calming music (30-minutes) for 12 weeks.   
c) Nominal cash reward is given to increase compliance.  A compliance of more 
than 80% is required.  
d) We will form the ADNI-EF composite score at baseline and after follow-up 
for comparison.   
 
2) To demonstrate that non-executive cognitive domains may be improved by a 
strengthened executive functioning network:  
 
a) We will perform neuropsychological testing and look at other domains namely 
visuospatial, language and memory to see if there are improvements.  
b) In our analysis, we will gauge what proportion is directly related to executive 
function improvements.  
 
3) To demonstrate changes in connectivity in response to cognitive training, we will 
correlate c-fMRI with ADNI-EF 
 
a) C-fMRI task positive imaging are constituents of ADNI-EF performance.   
b) A composite weighted high-performance network is formed as per CPM 
protocol.  
c) Show that there is increased strength of connectivity in the high-performance 
network. 
d) Show that changes in f-MRI correlate with changes in ADNI-EF scores.   
 
4.6 Expected outcomes 
 
1) We expect the ADNI-EF in the intensive intervention to change in the positive direction in 
the period of the study.  The non-intensive group may show minor changes.  The 
expectation of positive change comes from the relatively short period of the study, during 
which deterioration due to natural history is likely to be minimal.   
 
2) We expect increases in the connectivity measures in the high-performance network.   
 
4.7 Pitfalls  
 





2) We have not previously determined the maximum tolerated dose of intervention. However, 
from the literature and our clinical experience, it is somewhere between 1 and 2 hours.   
 
3) We have not performed a dose-response study. Given that interference is not a major issue 
in this single-task training, at worst, the highest tolerated dose may be partially redundant 
but is unlikely to have a negative effect.  With unlimited funds and time, both 2 and 3 
would have been proposed.   
 
4) The diagnostic criteria for CSVD are as not optimal and can often include other subcortical 
cognitive impairments in the cohort. 
 
5) CPM is a new and hitherto unproven technology.  
 




1) To our knowledge, our study will be the first to investigate in a cohort of MCI-CSVD the 
impact of combined meditation and Dual N-Back on executive functioning, provide 
biomarkers which may correspond to this change, and thus offer insight into executive 
function’s relationship to connectivity. 
 
2) We use a rigorously validated but underused measure, the ADNI-EF, which was developed 
by looking at the ADNI database.  The composite score allows us to use one endpoint as 
to minimize multiple comparisons and makes the experiment more rigorous.  
 
3) We use a highly innovative imaging biomarker, and if useful, it will open new possibilities 
for clinical trials in this area.   
 
4.9 Clinical and/or Public Health Significance 
 
CSVD form of vascular cognitive impairment represents one of the major causes of 
morbidity in our ever-aging population.  Presently there are no interventions which have been 
proven to improve cognition in this population.  Demonstration of benefits, however small given 
the number of people afflicted by this condition, will be greatly beneficial to public health.  
Additionally, the technique we are auditioning in this study include ADNI-EF and CPM 
have wider applications in other studies of cognitive training and rehabilitation and may lend 
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Figure 1.  Sample size calculation.  G*Power 3.1.9.2 software was used to calculate our sample 
size.  We ran ANOVA Repeated measures, between factors.  A priori power analysis computed 
that 74 participants would be needed to determine a significant difference between two groups 
with the study set at a 5% significance level, powered at 80%, and effect size-f set to 0.25.  The 
ADNI-EF test has not yet been studied in our sample population so we choose a medium effect 
size, Cohen f 0.25.1 Please see the above figure to view the input parameters we set.  The output 









Table 1.  Baseline characteristics of subjects who were randomized to the study. 
 
 Combined MMP 





Demographics Variables     
Female (%)     
Male (%)     
Age (years)  
(mean+ SD) 
    
Education (years)  
(mean+ SD) 
    
Clinical Variables     
Time Diagnosed with MCI 
Before Start of Study (weeks)  
(Mean + SD)   
    
Risk Factors for Developing 
Subcortical Dementia 
    
HTN (%)     
Type I DM (%)     
Type II DM (%)     
Average Hemoglobin A1C  
(Mean + SD)   
    
Obesity (%)     
Hyperlipidemia (%)     
Physically Inactive (%)      
Smoking (Packs-per- Year)  
(Mean + SD)   
    
Drinks Per Week (Mean + 
SD)    
    
APOE ε4 Alleles: Average 
Present 
(Mean + SD)    
     
Number of VaD Biomarkers 
Present:  
(Mean + SD)    
    
Severity of VCI     
Number of Clinical 
Symptoms Suggestive of 
CSVD 
(Mean + SD)    
    
Number of Cognitive 
Domains Impaired 
(Mean + SD)    
    
Neuropsychological and 
Behavioral Tests 
    
MOCA 
(Mean + SD)    
    
 Letter fluency (F, A and S)  
(Mean + SD)    
    
 Vigilance A  
(Mean + SD)    
    
Informant Questionnaire for 
Cognitive Decline in the 
Elderly 
 (Mean + SD)    
    
 Neuropsychiatric Symptom:  
Centre for Epidemiologic 
Studies-Depression Scale 
(CES-D) 
(Mean +/- SD) 
    
Beck Anxiety Inventory 
 (Mean +/- SD)  
    




Brain Parenchymal Fraction 
Volume 
(Mean +/- SD) 
    
Lacuna Volume  
(Mean +/- SD) 
    
White Mater 
Hyperintensities, Average 
Fazekas Score  
(Mean +/- SD) 
    
Other Factors     
Number of Medications 
Prescribed Within the Past 
Month that Affect Cognition 
(Mean +/- SD) 
    
Number of Medications 
Prescribed Within the Past 
Month that Affect Mood 
(Mean +/- SD) 
    
 
The Shapiro-Wilk test will be used to confirm that the random sample is normally distributed 
for each of the outcome variables studied. Student t-test will be used to confirm that mean 
variables are not significantly different between groups. Chi-square test will be used to 
confirm that dichotomous variables are not significantly different between groups. Wilcoxon 
rank-sum will be used to confirm that ordinal variables are not significantly different between 
groups. Factors that affect the primary outcome, ADNI-EF, will be controlled for by multiple 









Table 2.  Neuropsychological and behavioral tests used in this study.   
Study / 
Test 
No. of  
Healthy 
Participants 









Test Score Cut-off 
Values 
Test Validity  
Nasreddine, Z: 2 
MOCA 





Cut-off score = 
23.7±4.1 
To detect MCI: Sensitivity = 
90%, Specificity = 87%, 
Test-retest reliability= 
correlation coefficient=0.92, 
P<.001, Internal consistency 
Cronbach alpha = 0.83 
Letter fluency 
(F, A and S) 3,4 
N= 1343 
 









coefficients): r(42) = .95, and 
switching, r(42) = .96.4 
Vigilance A5 N = 50 Age = 79.9 
± 7.8 
Cut off-score > 27, 
significantly 
impaired vigilant (or 
sustained) attention 
Sensitivity = 75.0 (65.7–
82.8); Specificity = 73.1 
(72.4–90.1); Positive 
Predictive Value = 85.3 
(76.5–91.7); Negative 


















cut-off score of 65  
AUC of 0.666 (95% 
confidence interval (CI), 
0.601–0.732), 
sensitivity = 66.1%, 









Age > 65 Cut-off score of 16 Specificity = 90%, sensitivity 
= 86%, and a positive 
predictive value = 80 
Beck Anxiety 
Inventory8,9 









11.8  years 
Mild anxiety < 9 
points 
Internal consistency 
Cronbach’s alpha = 0.90 to 
0.94, retest reliability ranges 









Average Score = 
34.6±8.1 
p-valuec = <.001 




Average Score = 
7.4±2.2 








Average Score = 
45.7±10.2 
p-valuec = <.001 




Average Score = 
36.4±13.2 
p-valuec = <.001 




Average Score = 
89.2±44.3 










Average score = 
12.0 (SD+/-2.46) 
Relatively reliable when 










Age >65 Mean depression 
score = 0.25, mean 
disinhibition score = 
0.13, mean 
irritability score = 
0.05 
Test-retest scores =  0.79 for 
frequency (p = 0.0001) and 












Dementia group = 
25.36 
P< 0.01, when age and 
education are adjusted (F 









(n) = 10,741 




16 years of 
education: normal 
≥9; early MCI = 9–
11; AD ≤8 
 
8–15 years of 
education: normal 
≥5; early MCI = 5–
9; AD ≤4 
 
0–7 years of 
education: normal 
≥3; early MCI = 3–
6; AD ≤2 
AUC area under the receiver 
operating characteristic curve 
Early MCI in ADNI 
16+ years of education: 0.72 





N = 1108 
MCI 
participants  






from MCI, cut-off 
point of 5/6 
ROC analysis = area under 
the curve of 0.903, sensitivity 
= 80.3%, specificity = 87.0%, 
classification accuracy = 
84.7%  
 
We reported  normative values from cognitively healthy, elderly participants because a memory 
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     (B) 
 
 
Figure 2.  The steps into making an Executive Function Network Linear Model.  
A) BOLD signal will be measured from each participant as they complete the ADNI-EF test and will be computed into a program as a 
functional connectivity matrix.  Image was taken from “Relating Brain Circuits to Behavior: David Van Essen at TEDxCaltech.”18   
B) BOLD average signal time will be calculated in each voxel, or node.  The strength of connection between nodes represents the matrix.  
We will input each subject’s connectivity matrix and ADNI-EF scores into our executive functioning connectivity predictor model.  With 
the aggregated data, we can then compute a robust regression to show the association between ADNI-EF z-scores and the connectivity 
matrix (p<0.01).  By applying significance testing, edge strengths in the positive tail will be summed together to produce the predictive 
positive network strength, and the edge strengths in the negative tail will be summed together to produce the predictive nega tive 
network strength.  Positive and negative network strengths can predict ADNI-EF z-scores by applying the “leave-one-out cross 
validation method.”19  The linear network strengths that significantly correlate (p<0.01) functional connectivity to ADNI-EF z-scores 
can then be used to predict ADNI-EF z-scores in new subjects.  Image was taken from “Using connectome-based predictive modeling 
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Figure 3.  How to calculate composite ADNI-EF scores for each intervention group.   
The first step is to calculate “Original EF Scores” for each participant.  To calculate “Original EF 
Score,” each of the six tests will need to be graded per its instructed protocol.  Each test’s final 
score is assigned a numerical categorical value, which is listed above on the first line.  Original EF 
score will be calculated by adding the categorical values from the six tests and then dividing by six.  
After we determine each participant’s “Original EF score,” we will then calculate composite ADNI-
EF score for the two intervention groups. For each intervention, we will add the “Original EF” 
scores and then divide by total number of participants in that intervention group.  The above figure 
came from the study “A composite score for executive functioning, validated in Alzheimer’s 
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Table 3.  Summary on review of the literature 
 
Study Age and 
Cognitive 
Status 








MMP-Donepezil (n=42);  
Cognitive- Donepezil 
(n=38); PMR- Donepezil 
(n=45); Donepezil-Only 
(n=43). 
288 sessions total, 
each session 
90 minutes 
Education, age, APOE 




Primary outcome: delay cognitive 
decline as measured by MMSE 
and CAMCOG scores, 
significance determined by 
Repeated-measures ANOVA (p < 
0.05) and Cohen’s d 
 
CAMCOG measures spatial 
memory, language, memory, 
perception, attention, and praxia    
MMP-Donepezil was the only 
intervention whose Cohen effect 
sized on MMSE (Cohen D= 1.45) 
and CAMCOG (Cohen D= 1.73) 
scores remained steady throughout 
the two-year study in the mild-
moderate dementia group.  These 
scores declined significantly at 18 
months in the Cognitive 
Stimulation-Donepezil group and 
at 6 months in the Donepezil-only 
and PMR-Donepezil groups.  These 
interventions had no significant 
effects in moderate-severe 
dementia. 
Course-Choi 22 Control: M = 
27; N-back: M 






MMP-Dual N-Back (n=15); 
sham-control group non-
adaptive 1-back task (n=15); 
MMP (n=15); Dual N-Back 
group(n=15) 
 




1-back task  
Total of 5 hours 
across 7 days; post-
follow up seven day 
after the study 
completed 
 
Dual N-Back: 24 




audio clip  
Sham-group: 24 




Baseline differences in 
anxiety scores, age, and 
gender 
Outcomes:  Attention (measured 
by anti-saccade task); 
performance (mean difference in 
Dual N-Back performance 
between groups over 7 days); and, 
worrisome behavior (measured by 
STAI trait worry scores)   
 
Significance determined by mixed 




Participants in combined group 
experienced significant most 
improvements in Dual N-Back 
performance (t(14) = 4.98, p < 
0.001 (p<0.05) and decreases in 
STAI trait worry scores (t(14) = 
5.35, p < 0.001); and, this was the 
only intervention group were a 
significant correlation was 
observed between attention and 
STAI trait worry scores (r = −0.36, 
N = 30, p = 0.05) and an almost 
significant correlation between 
trait worry scores and improved 
performance (p=0.07) 
Willis, S. 23 Memory: M= 
74 y/o; Speed: 
M= 73 y/o; 
Reasoning: M= 
74 y/o; 
Speed-processing (n = 702): 
visual search and divided 
attention;  







minutes long at 
beginning of study 
Sex, education, age, 
MMSE score, health 
status, and Short-Form-36-
Physical Function score. 
Outcomes: Memory (measured by 
Hopkins Verbal Learning Test, 
Rey Auditory-Verbal Learning 
Test, and the Rivermead 
Behavioral Paragraph Recall test); 
Reasoning (measured by letter 
Memory (effect size, 0.23 [99% CI, 
0.11-0.35), speed-processing (0.76 
[99% CI, 0.62-0.90), and 
reasoning training (effect size, 0.26 
[99% CI, 0.17-0.35]) significantly 








training (n = 699): 
remembering and finding 
patterns over trials; and, 
Control Group- no contact 




sessions in addition 
to four, 75 minutes 
sessions at 11 and 
35 months  
 
Outcomes were 
collected yearly for 
five years 
series, letter sets, and word 
series); Speed of processing 
(measured by 3 field of view 
subscales); and,  
Functional outcomes: IADL 
difficulty (measured by the 
Minimum Data Set–Home Care).  
 
Modified intention-to-treat 
protocol, significance calculated 
by repeated-measures, mixed-
effects model, and Bonferroni 
(p<0.01)  
within that cognitive domain.  The 
effect sizes remained over five 
years compared to the control 
group-no contact. 
Salminen, T. 24 Dual N-Back: 













Control group- no contact 
(n= 21); 
Dual N-Back (n= 26) 
 
Exploratory analyses: 
Dual N-Back young adults 
(n=20) 
Control-Group young adults 
(n=18) 
14 sessions, 50 
minutes in duration 
Cognitive differences 
(assessed by MMSE >28 
and Mehrfachwahl-
Wortschatz-Intelligenz 
test>110), years of 
education, years in 
occupation, age, and 
gender 
Outcomes: Executive functioning 
(defined by reaction times and 
error rates in attentional blink, 





subject factors: Group; Within-
subject factors: Session (pretest 
vs. posttest)) and Cohen’s d (p < 
.01) 
 
Dual N-Back significantly 
improved the three executive 
functioning task scores in 
comparison to the control group 
(p<0.01).  
 
The game’s plasticity was assessed 
by comparing post-test 
performance scores in the elderly 
who received Dual N-Back with the 
younger adult’s pre-test scores who 
received Dual N-Back: no 
significant difference between the 
two groups was found (p>0.05), 
despite significant differences 
between their pre-test scores (M = 
1.64 and M = 2.34, respectively), [t 




MMSE >27 T2DM (n=20); Control 
group (n=19); f-MRI data 
obtained during resting state 
and digital 1-back WM task  
One-day: 1 
instructional trial, 
11 practice trials, 
and 12 test trials     
Clinical variables (HbA1c, 
lipid panel, and HTN), 
cognitive status (MMSE), 
performance with Dual N-
Back, symptoms of anxiety 
and depression (Self-
Rating Anxiety Scale and 
Self-Rating Depressive 
Scale), Short-term memory 
performance, age, gender, 
and education. 
Outcomes: Differences in 
working memory systems’ 
activity levels, as measured by β-
estimates, between groups during 
the 1-back task and AVLT test. 
Significance was determined by 
two-sample t-tests and Cohen’s d. 
Differences in functional 
connectivity in working memory 
systems between groups were 
compared, as assessed by voxel-
wise one-sample t-test and 
Cohen’s d (p< 0.05)  
Significantly lower BOLD signals 
during the 1-back task was 
observed in T2DM patients’ in the 
bilateral lingual gyri, the left 
ventral lateral prefrontal cortex, 
the inferior parietal lobule, and in 
the right fronto-parietal network’s 
connection with the lingual gyri 
(P < 0.05, AlphaSim correction).  
However, these areas became 
significantly more activated when 
completing the short memory tasks 
in comparison to euglycemic 
patients.  The fronto-parietal 
network’s increase in amplitude of 
activity was significantly correlated 
with improved AVLT short-term 




Salminen, T. 26 Dual N-Back: 
M= 24 y/o; 
Active control 
group/ single-
back: M= 24; 
Control-No 
contact: M= 25 
Dual N-Back (n=20); Active 
control group/ single-back 
(n=18); and, Control-No 
contact (n=18) 
16 sessions, thirty-
minutes in duration: 
in each session, 
Dual N-Back and 
single n-Back 
participants 
received 20 practice 
trials and 12 test 
trials 
   
Age and sex Outcomes: Changes in white 
matter density, as measured by 
fractional anisotropy and mean 
diffusivity; correlation between 
changes in white matter and Dual 
N-Back performance 
 
Intention-to-treat protocol, group 
× time effects (p<0.05) 
Significantly higher mean changes 
in fractional anisotropy values 
were observed in the Dual N-Back 
group when compared to both 
single-Back group and passive 
control group (p<0.05).  
Significant increases in FA were 
observed in the superior and 
inferior longitudinal fasciculi, the 
inferior fronto-occipital fasciculus, 
the forceps minor, and the 
corticospinal tract.  The increases 
in FA were not significantly 
correlated with mean improved 
changed in Dual N-Back scores (p 
> .57).  The study also did not find 
significant differences in mean 
diffusivity values. 
Hölzel, B.  
27 
 
MBSR: M= 39; 










MBSR (N=15); Control 
group-stress management 
education (n=14)  
MBSR (N=15): 
Once a week, 2-




take about 1000 
minutes to 







Once a week, 2-
hour class session; 
weekly homework 
assignments that 
take about 1000 
minutes to 
complete; and, one 
eight-hour retreat 
day 
Age, gender, education 
level, comorbid anxiety 
diseases, SSRI’s, hand-
dominance    
 
 
Outcomes: Reduced anxiety 
(measured by decreases in pre-
post Beck Anxiety Inventory and 
Perceived Stress Scale scores); 
mean change in BOLD signal; 
correlation between anxiety 
scores and areas in the brain that 
underwent significant changes in 
activity levels; and, differences in 
brain activity between GAD 
participants and healthy 





MMP significantly reduced BAI 
and PSS scores in comparison to 
the control group (ANOVA: group 
x time, p<0.05).  MMP caused 
significant mean increases in 
BOLD signal in the right pars 
opercularis, left pars triangularis, 
and right rostral middle frontal 
cortex in comparison to the control 
group.  These activated areas were 
significantly correlated with mean 
changes in BAI scores, but not PSS 
scores.  The BAI scores were also 
significantly correlated to the right 
amygdala strengthening its 
functional connectivity with the left 
rostral middle frontal cortex (ρ = − 
.648, p < .001), the right rostral 
middle frontal cortex (ρ = − .487, p 
= .018), and the right superior 
frontal cortex (ρ = − .424, p = 
.044) (ANOVA group-by-time 
interaction and Spearman's ρ 
(0.05).   
 
Differences in brain activity 
between GAD participants and 
healthy participants was assessed 
by comparing combined GAD 
imaging data to newly enrolled 
healthy participants’.  Healthy 




demographic variables.  At 
baseline, GAD participants’ right 
amygdala activity was significantly 
higher when viewing neutral faces 
in comparison to healthy 
participants’ (p = 0.0001).  The 
right amygdala, the right caudal 
middle frontal (p = 0.009) and the 
right lateral orbitofrontal cortex 
areas (p = 0.0054) underwent 
significantly lower pre-post BOLD 
signals in comparison to healthy 
participants’.  These changes were 
not significantly correlated to BAI 
index scores. 
Wetherell, J. 28 MMP: M= 70 
y.o; Control: 





MMP (n= 47): Baseline 
characteristics: WTAR score 
= 37.7 (8.5); Memory 
composite score = -0.07 
(0.68); Verbal fluency = -
0.205 (0.899); Stroop = 
0.077 (0.954); Digit Span = 
10.1 (2.7); Grooved = 105.1 
(38.8); Peak cortisol 
(ng/mL) = 5.2 (2.5); 
PROMIS Anxiety = 20.8 
(5.8); PSWQ = 28.4 (6.6) 
 
Control Group (n= 56): 
Baseline characteristics: 
WTAR score= 40.6 (8.2); 
Memory composite score = -
0.23 (0.85); Verbal fluency 
= -0.0900 (1.0); Stroop= 
0.088 (1.149); Digit Span = 
10.0 (2.8); Grooved = 105.0 
(27.6); Peak cortisol 
(ng/mL) = 4.9 (2.4); 
PROMIS Anxiety = 19.9 
(7.1); PSWQ = 27.7 (8.2) 
 
MMP (n= 47): 8 
weekly sessions, 90 





Control Group (n= 
56): Health classes 
= 8 weekly 
sessions, 90 minutes 




Age, clinical variables, 
gender, education, 
medications that can affect 
mood and cognition, 
cognitive differences at 
baseline (assessed by the 
PROMIS scale, Wechsler 
Test of Adult Reading, 
Digit Span subtest, 
Grooved Pegboard Test, 
Memory composite test, 
and Cognitive control 
composite test), prior 
experiences with 
mindfulness or yoga 
practice or yoga, and 
regular use of corticoid 
steroids.    
Primary outcomes: 1) Mean 
change over time on memory and 
cognitive control composite 
scores between groups.  Memory 
composite scores were measured 
by Immediate List, Immediate 
story, Delayed list, and Delayed 
Story.  Cognitive control 
composite scores were measured 
by Verbal fluency, and Stroop: 
Color-Word.  2) Mean change 
over time between-groups on the 
Digit Span and Grooved 
Pegboard.  Primary outcomes 
were analyzed by covariance 
models that controlled for 
baseline score, condition, and 
WTAR scores (p<0.05).   
 
Secondary Outcomes: 1) Mean 
change over time on anxiety and 
depression scores, which were 
assessed by PSWQ, PROMIS 
Depression, and PROMIS 
Anxiety.  These outcomes were 
analyzed by mixed effect models 
(p<0.05).  2) Mean change in peak 
cortisol levels between groups, 
assessed by paired t-test (p<0.05) 
 
Intention-to-treat analysis 
MMP caused significant 
improvements in memory 
composite scores (p<0.046, effect 
size = 0.28), PSWQ scores 
(p<0.042, Effect size=-0.48), and 
PROMIS Anxiety scores (p<0.061, 
effect size = -0.42).  A significant 
correlation was found between 
improvements in memory 
composite scores and changes in 
anxiety and depression scores (χ21 
=4.5, P = .03).  Significant 
decreases in cortisol levels were 
observed in the MMP group 
(paired t = 3.8, P = .0015).    
 
No significant differences were 
observed in Digit Span scores 
between groups (p<0.99, effect 
size=-0.09) 
Newberg, A.29 MMP- Kirtan 
Kriya: M = 64 
± 8 years old, 
MMP- Kirtan Kriya (N=7): 
Baseline characteristics: 
Category Fluency-Animals 
= 21.1 ± 7.9; Trails A = 30.5 
8 week-long study 
MMP-Kirtan Kriya 
(n=7): 12 minutes 
of Kirtan Kriya 
Age, cognitive outcome 
measures, MMSE scores 
<16, and prior experience 
with meditation or yoga 
Outcomes:  Mean changes in test 
scores within-groups on Category 
Fluency task, Wechsler Adult 
Intelligence Scale, Digit Symbol 
Kirtan Kriya: Significant findings 
between changes in CBF and test 
score improvements were observed 




MMSE = 28.1 
± 0.7  
Placebo-Music 
group: M = 
65.0 ± 9., 






± 12.2; Trails B= 105.5 ± 
52; Digit Symbol = 63.7 ± 
25.3; Logical Memory 
Delayed = 10.6 ± 5.2; and, 
POMS = 52.2 ± 12.9      
Placebo-Music Group (n=7): 
Baseline Characteristics: 
Category Fluency-Animals 
= 21.5 ± 5.0; Trails A = 37.0 
± 11.7; Trails B= 132.5 ± 
58; Digit Symbol = 67.6 ± 
21; Logical Memory 
Delayed = 12.3 ± 6.5; and, 
POMS = 47.5 ± 17.2 
 
daily; Placebo-
Music (n=7): 12 
minutes of listening 
to a neutral stimulus 
daily   
 
Substitution Test, Logical 
Memory task, Trails A, and Trails 
B (paired t-test, p < 0.05); 
correlation between imaging and 
neuropsychological test scores 
(Pearson’s correlation, p<0.05); 
and, mean changes in cerebral 
blood flow within groups in 
regions of interest (paired t-test, p 
< 0.05). Regions of interest 
included the inferior frontal, 
superior frontal, superior parietal, 
DLPFC sensorimotor, posterior 
cingulate, orbitofrontal, anterior 
cingulate, superior frontal 
thalamus, superior parietal, 
medial frontal, and amygdala 
precuneus.  
prefrontal cortex - Trails B task (R 
= −0.61, p = 0.02); left thalamus - 
Trails B task (R = −0.62, p = 
0.02); and, left thalamus - Digit 
Span Test (R = 0.56, p = 0.03)  
No significant findings (changes in 
CBF or neuropsychological test 
scores or correlations) were 
observed in the music group 
Chen, X. 30 Donepezil: M= 
75 y/o, MMSE 
= 29.8 
 
Placebo: M = 
67 y/o, 
MMSE= 29.6  
 







titrated to 10 mg 
daily over six weeks 
and then continued 
10 mg daily dose 







Age, baseline cognitive 
test scores, education, and 
gender.      
 
Outcomes: Mean changes in 
cerebral blood flow during verbal 
memory task and HVLT test, as 
assessed by GE Signa 1.5T MR 
scanner (independent-sample t 
tests without correction, p<0.05) 
Donepezil did not cause significant 
changes in cerebral blood flow 
during the HVLT test in 
comparison to the place group 
(p>0.05).  Performance on the 
HVLT remained stable in the 
placebo group but increased in the 
Donepezil group.  However, 
donepezil did cause a significantly 
less decline in cerebral blood flow 
during the verbal memory task in 
comparison to the placebo group.  
In the Donepezil group, 
participants had a -1.32-mean 
decline in the left temporal tissue 
and a -1.44-mean decline in the left 
frontal tissue in comparison to the 
placebo group’s -3.13 mean 
decline in the left frontal tissue and 
-2.83 mean decline in the left 




Placebo: M = 
74 y/o;  
 
Donepezil 




10mg: M= 76 
y/o,  
 
Placebo (n=193): Baseline 
characteristics in scores: 
Hachinski score= 9.6 ± 0.2; 
ADAS-cog= 18.8 ± 0.7; 
MMSE= 22.2 ± 0.3; CDR-
SB= 5.6 ± 0.2; ADFACS= 
15.1 ± 0.7 
 
Donepezil 5mg (n=208): 
Baseline characteristics in 
scores: Hachinski score = 
Donepezil 5mg 
(n=208): 5 mg 
nightly for 24 
weeks 
Donepezil 10 mg 
(215):  5 mg nightly 
for 4 weeks 
followed by 10 
mg/nightly until 
week 24 
Placebo group= 193 
Demographic 
characteristics, clinical 
variables, medications, and 
neuropsychological tests 
(Hachinski score, ADAS-
cog, MMSE, CDR-SB, and 
ADFACS) 
Primary Outcomes: Mean change 
from baseline scores on the 
ADAS-cog and CIBIC-plus tests.  
 
Secondary Outcomes: Mean 
changes from baseline on MMSE, 
CDR-SB, and ADFACS tests 
 
Intent-to-treat (ITT) analysis 
between groups (p<0.05); study 
completion rate was 79.7% 
Significant mean changes in 
improvement from baseline ADAS-
cog scores were observed in the 
Donepezil 5mg group ( −2.65 ± 
0.48 at week) and Donepezil 10mg 
group (−2.19 ± 0.44) but not the 
placebo group (−0.10 ± 0.39) at 
the end of the study (p<0.001).  
Significant mean changes in 
improvement from baseline MMSE 









9.4 ± 0.2; ADAS-cog= 20.8 
± 0.7; MMSE= 21.8 ± 0.3; 
CDR-SB= 6.0 ± 0.2; 
ADFACS= 15.7 ± 0.7 
 
Donepezil 10mg (n=215): 
Baseline characteristics in 
scores: Hachinski score= 9.5 
± 0.2; ADAS-cog= 20.6 ± 
0.7; MMSE= 21.5 ± 0.3; 
CDR-SB= 6.1 ± 0.2; 
ADFACS= 16.1 ± 0.7 
 
Reductions in doses 
was not permitted  
Outcomes collected 






Donepezil groups at the end of the 
study but not in the placebo group 
(p<0.01).  Significant mean 
changes in improvement from 
baseline CDR-SB scores was only 
observed in the Donepezil 10mg at 
the end of the study.  No significant 
improvements in ADFACS scores 
were observed in the three groups 
at the end of the study (p>0.05).  
Donepezil appears to be safe in 
participants because there were no 
significant differences in adverse 
events between the three groups.  
Most common adverse events 
included nausea, abnormal dreams, 




Ngandu, T 32 Multidomain: 





Multidomain group (n= 
591): Baseline scores: NTB 
Total score= –0·03 (0·55); 
Executive functioning= –
0·03 (0·66); Processing 
speed = –0·02 (0·78); and, 
Memory = –0·03 (0·68) 
   
Control group (n=599): 
Baseline scores: NTB Total 
score= 0·03 (0·59); 
Executive functioning= 0·03 
(0·69); Processing speed = 
0·05 (0·84); and, Memory = 
0·03 (0·66).  
 
Multidomain group: 
Diet (based on 
Finnish Nutrition 
Recommendations- 
10 dietary eating 
sessions); Physical 
exercise (based on 
Dose Responses to 
Exercise Training 
study protocol: 1-3 
times per week 
muscle strength 
training and 2-5 
times per week 
aerobic exercise); 
Computer-based 
training: 72 sessions 
(three times per 
week, 10-15 
minutes per 
session).  This was 
conducted again 6 
months later into 





mental speed.  
Management of 
Age, education, MMSE 
scores, vascular and 
lifestyle risk factors, and 
cognitive differences (NTB 
total score, executive 
functioning, processing 
speed, and memory). 
Primary Outcomes: mean change 
and estimated mean change in 
NTB scores at 24 months between 
groups (group × time interaction, 
P<0.05)  
 
Secondary outcomes: mean 
change and estimated mean 
change in executive functioning 
scores, processing speed scores, 
and memory scores between 
groups at 24 months (between 
group differences, p<0.05).    
 
Executive functioning was 
measured by: digit span, concept 
shifting test (condition C), trail 
making test (shifting score B –
 A), and shortened Stroop tests. 
  
Processing speed was measured 
by: letter digit substitution test, 
concept shifting test (condition 
A), and Stroop test (condition 2).  
 
Modified intention-to-treat to 
account for missing data (p<0.05) 
The multidomain group’s estimated 
mean change in NTB total z-score 
at 2 years was 0.20 (SE 0.01, SD 
0.51), and it was 0.16 (0.01, 0.51) 
in the control group.  The mean 
difference in NTB total scores per 
year between groups was 0.022 
(95%CI 0.002–0.042, p=0.030).  
Multidomain approach 
significantly affected executive 
functioning scores (p=0.039) and 
processing speed scores (p=0.029).  
The control group’s risk for decline 
in NTB total score (odds ratio 1.31, 
95% CI 1.01–1.71), executive 
functioning, and processing speed 
were significant in comparison to 






vascular risk factors 






classes given at start 
of study and months 




at baseline, and at 6, 
12, and 24 months 
Gibbons, L.10 Healthy: M= 
76 y/o; MCI: 
M= 75 y/o; 
AD: M= 75 y/o  
 
Healthy (n= 229): Baseline 
characteristics: Education = 
16 years; APOE allele = 
27%; ADNI-EF score = 
0.70±0.67; Category 
Fluency Combined = 
34.6±8.1; WAIS-R Digit 
Symbol = 45.7±10.2; Digit 
Span Backwards = 7.4±2.2; 
Trails A = 36.4±13; Trails B 
= 89.2±44.3; Clock Drawing 
= 4.7±0.6; and, white matter 
hyperintensities (cm3) = 
0.68±2.34.   
 
MCI (n= 390): Baseline 
characteristics: Education = 
16 years; APOE allele = 
54%; ADNI-EF = 
−0.03±0.77; Category 
Fluency Combined = 
26.7±7.3; WAIS-R Digit 
Symbol = 36.9±11.2; Digit 
Span Backwards = 6.2±2.0; 
Trails A = 44.3±21.7; Trails 
B = 131.0±73.5; Clock 
Drawing = 4.7±0.6; and, 
white matter 
hyperintensities (cm3) = 
0.60±1.09 
 
AD (n= 181) 
Outcomes collected 
at baseline and at 
months 6, 12, 18, 
24, and 36  
Age, education, sex, and 
the presence of one or 
more APOE ε4 alleles 
 
 
Outcomes: Validate the utility of 
ADNI-EF z-scores, defined as: 1) 
find a significant correlation 
between ADNI-EF scores and 
detecting MCI-AD conversion; 2) 
find a significant correlation 
between baseline ADNI-EF z-
scores and MRI images from 
selected brain regions:  
Regression models, controlling 
for age, education, sex, one or 
more APOE alleles, and 
intracranial volume, were used to 
predict EF z-scores. White matter 
hyperintensities were transformed 
to log scale.  Robust standard 
errors were used (p<0.05).  3) 
determine ADNI-EF scores ability 
to detect change over time 
 
 
Criteria for inclusion into data 
analysis: all outcome measures 
obtained from at least one visit   
Results of Interest: ADNI-EF z 
scores were significantly correlated 
to MRI changes in the Caudal 
Middle Frontal (2.29); Rostral 
Middle Frontal (3.52); Superior 
Middle Frontal (2.88); Lateral 
Orbito-frontal (3.8); Medial 
Orbito-Frontal = 2.34; and, Pars-
Triangularis (2.61); and, 
significantly correlated with 
changes in white matter hyper-
intensities (WMI) (−2.09) 
(p<0.05).  WAIS-R Digit Symbol 
had the strongest correlation with 
WMH (−2.31); Clock Drawing had 
the strongest correlation with 
thickness in the caudal middle 
frontal regions (3.14); and, the 
Trails had a strong correlation 
with the rostral (3.73) and superior 
middle frontal (3.14) regions and 






Sam 33 Age range: 50–
91 years old 
75 participants, participants 
enrolled were confirmed to 
have moderate to severe 
leukoaraiosis with no 
cortical infarcts or white 
mater lesions > 2cm and 
Fazekas score > 2    
Outcomes collected 
at one session 




reactivity (CVR)’s correlation 
with white mater tissue integrity 
 
Repeated-measures one-way 
analysis of variance (ANOVA) 
with dependent variable defined 
as MRI parameters and 
independent variable defined as 
regions of interest.  
Mauchly test and corrections were 
made with Greenhouse-Geisser.  
Significance set to per-
comparison p value 
<0.05/3comparisons= 0.0167. 
Bonferroni-corrected.   
Negative CVR is significantly 
correlated with decreased FA, 








We will measure alterations in white matter microstructure by using DTI-DSC imaging, 
and we will measure cerebral blood flow by using BOLD f-MRI. BOLD imaging data will 
generate a map of long-distance connections between one area of grey matter to another and will 
provide information on functional connectivity. DTI- DSC images will provide information on 
structural connectivity. Informatics platforms are provided through the Human Connectome 
Project, a project funded by the NIH. We will use 3T GE MRI scanners with an 8-channel phased 
head coil to image participants.34 Prior to imaging, participants will be injected with a single dose 
of imaging contrast, 0.1 mmol/kg of gadolinium, and will be asked to abstain from ingesting 
caffeinated products eight hours before imaging. 34 We will follow the same imaging protocol 
from a study that used DTI- DSC imaging, which is called “Cerebrovascular reactivity and white 
matter integrity.” We will use the following eight image sequences from that study.34 Total 
imaging time is about one-hour long for each participant.18   
 
1) T1-weighted 3D spoiled gradient echo sequence: Slice thickness: 1.5 mm; no interslice gap; 
matrix size:  256 × 256; field of view: 22 × 22 cm; flip angle: 8/20°; echo time (TE): 2.3/3 ms; and, 
repetition time (TR): 7.8/9.5 ms  
2) BOLD fMRI using a T2*-weighted echoplanar imaging gradient echo sequence: Slice thickness: 
3.0/5.0 mm; field of view: 24 × 24 cm; matrix size: 64 × 64; flip angle: 85/90°; TE 30 ms; and, TR 
2,000 ms  
3) FLAIR images: Slice thickness: 3 mm; slices per volume: 36–52; no interslice gap; matrix size: 
256 × 224/240 × 240; field of view: 22 × 22 cm; flip angle: 90°; TE 125/165 ms; TR 9,000/9,145 
ms; and inversion time 2,200/2,800 ms 
4) Diffusion tensor imaging with echoplanar imaging spin-echo sequence: Slice thickness: 3 mm; 




gradients: 23; non-diffusion-weighted B0 image: 2; TE 55/80 ms; and, TR 9,150/14,500 ms  
5) Proton density/T2-weighted images using fast spin echo-XL sequence: Slice thickness: 3 mm; 
matrix size: 128 × 128/256 × 209; field of view: 22 × 22 cm; flip angle: 90°; TE: 11.1/90 to 11/102 
ms; TR: 2,500/7,200 ms  
6) Multiecho T2 mapping using a fast spin echo-XL sequence: Slice thickness: 3 mm; no interslice 
gap; matrix size: 256 × 192; field of view: 230 × 184/22 × 22 cm; TE: 13, 26, 39, 52, 65, 78, 91, 
104, 117, 130, 143, 156 ms; and, TR: 5,000/6,000 ms 
7) DSC perfusion scan using gradient-multiphase echo echoplanar imaging sequence: Slice 
thickness: 5 mm; matrix size: 128 × 128; field of view: 27 × 27 cm; flip angle: 90°; TE: 31.5 ms; 
TR: 1,725 ms; and, 50 slices per location 
Image Reconstruction. 
Each subject’s MRI data will be uploaded to image processing software for pre-processing 
and data analysis.  Images will be pre-processed for quality control, which will be assessed by the 
same standards as in the ADNI-EF35 and Connectome Predictor Modeling studies.19  Image quality 
will be evaluated quantitatively by boundary shift integral, voxel‐based morphometry, tensor‐based 
morphometry, atlas‐based mapped volumetric, a measure of gray‐white matter contrast to noise, 
and size of head motion movements.35  Images also will be evaluated qualitatively by having a 
radiologist assess for the presence of artifacts, blurring/ghosting, flow artifact, intensity and 
homogeneity, and gray‐white CSF contrast.35  Only images with mild to no-artifacts will be used. 
Other images that will not be included in data analysis are: images from subjects with missing 
ADNI-EF scores, one or more missing nodal data, and head artifacts greater than 0.06 mm.19   
DTI- DSC Images-Structural Connectivity.  To quantify cerebral white matter dysfunction, 
T2 image sequences will be used.  T2 images will be measured with multi-echo fast spin-echo 
sequence.34  T2 images will be pre-processed with a product called “FMRIB's Diffusion Toolbox 
(FDT)” to improve quality image.34 




imported into FSL software for pre-processing and measurement calculations.34  Cerebral blood 
flow maps will come from the time-signal attenuation data obtained from the preprocessed 
weighted images.  The area of perfusion that will be assessed is from the middle cerebral artery.34  
BOLD-Functional-Connectivity.  Each subject’s MR-images will be pre-processed and 
analyzed in AFNI and FSL softwares.36 Pre-processing will include slice timing correction, 
motion correction through a general linear model, correcting signal-to-noise ratio, and 
controlling for anatomical variability across subjects with the “Gaussian smoothing filter” set 
at 6 mm.36  The imaging software will enable us to smooth out the cortex’s convoluted surfaces 
and view portions of the brain in left and right hemisphere surfaces and volume slices to view 
subcortical structures.18  The representation of the brain’s shape will remain preserved.18  We will 
use left and right hemisphere surface maps combined with volume slices to visualize and analyze 
functional MRI.18  BOLD data will be analyzed within our regions of interest in these right and left 
hemisphere surfaces and in subcortical, cerebellar, and cortical ribbon f-MRI views.18   
Combining Participant’s Images.  We will aggregate  participants’ BOLD and T2-
weighted images by pre-processing them in SPM8 software and FSL.36  To help align subject 
data, myelin map data will be used because they have landmarks that help align cortical areas 
between subjects.18   Myelin maps of activity will be generated by dividing the intensity value of 
T1-Weighted images from the intensity value of T2-Weighted images.18  Red myelin indicates a 
heavily, active myelinated region.18  The myelin map will then be compared to functional 
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Beck Anxiety Inventory 
  
Below is a list of common symptoms of anxiety.  Please carefully read each item in the list.  
Indicate how much you have been bothered by that symptom during the past month, including 
today, by circling the number in the corresponding space in the column next to each 
symptom.  
  
  Not at all  Mildly but it 
didn’t bother 
me much.   
Moderately - it 
wasn’t pleasant at 
times  
Severely – it 
bothered me a 
lot  
Numbness or tingling  0  1  2  3  
Feeling hot  0  1  2  3  
Wobbliness in legs  0  1  2  3  
Unable to relax  0  1  2  3  
Fear of worst 
happening  
0  1  2  3  
Dizzy or lightheaded  0  1  2  3  
Heart pounding/racing  0  1  2  3  
Unsteady  0  1  2  3  
Terrified or afraid  0  1  2  3  
Nervous  0  1  2  3  
Feeling of choking  0  1  2  3  
Hands trembling  0  1  2  3  
Shaky / unsteady  0  1  2  3  
Fear of losing control  0  1  2  3  
Difficulty in breathing  0  1  2  3  
Fear of dying  0  1  2  3  
Scared  0  1  2  3  
Indigestion  0  1  2  3  
Faint / lightheaded  0  1  2  3  
Face flushed  0  1  2  3  
Hot/cold sweats  0  1  2  3  
Column Sum          
  
Scoring - Sum each column.  Then sum the column totals to achieve a grand score.  Write 






A grand sum between 0 – 21 indicates very low anxiety.  That is usually a good thing.  However, 
it is possible that you might be unrealistic in either your assessment which would be denial or 
that you have learned to “mask” the symptoms commonly associated with anxiety.  Too little 
“anxiety” could indicate that you are detached from yourself, others, or your environment.    
  
A grand sum between 22 – 35 indicates moderate anxiety.  Your body is trying to tell you 
something.  Look for patterns as to when and why you experience the symptoms described 
above.  For example, if it occurs prior to public speaking and your job requires a lot of 
presentations, you may want to find ways to calm yourself before speaking or let others do 
some of the presentations.  You may have some conflict issues that need to be resolved.  
Clearly, it is not “panic” time but you may want to find ways to manage the stress you feel.  
  
A grand sum that exceeds 36 is a potential cause for concern.  Again, look for patterns or times 
when you tend to feel the symptoms you have circled.  Persistent and high anxiety is not a sign 
of personal weakness or failure.  It is, however, something that needs to be proactively treated 
or there could be significant impacts to you mentally and physically.  You may want to consult 




































Beck Anxiety Inventory® Aaron T. Beck. Publication Date: 1990, 1993   
 
 
CATEGORY FLUENCY TEST  




The instructor will say the following:  
“I’m going to give you a category and ask you to name all the different examples that you can 
think of from that category in one minute. For instance, if I said flowers, you might say rose, 
daisy, etc. Do you understand?”  
  
“Now go ahead and tell me all the different ANIMALS you can think of.”  
 
Procedure:  
1) Time for 60 seconds and tape record all responses.   
2) If the person stops before 60 seconds, say “Any more animals?” 
3) If the person says nothing for 15 seconds, say “A dog is an animal. Can you tell me more 
animals?” 
4) Repeat the above instructions for the category vegetable. 
  
Notes  
1. Write down everything that the subject says, including comments 
2. Note down the corresponding times at which the participant provides an answer   
3. If participants ask questions during the test, instructors may provide brief answers  
4. If subjects stop before the minute is over, encourage them to continue with the task.  
If subjects continue to refuse, say “There are a few seconds left, so we’ll just let the 
time run on.”   
  
  






















Sager MD, MA; Hermann PhD, BP; LaRue PhD, A; Woodard PhD, JL, Screening for 
Dementia in Community-based Memory Clinics. Wisconsin Medical Journal 2006.105(7)25-
29   
 
 




Scoring: Count the total number of animals but do not include repetitions or non-animal words. 




Scoring: Count the total number of vegetables but do not include repetitions or non-vegetable 
words. 
Total score: __________ 
 
Note: A score less than 14 is abnormal.  
 
Directions for Scoring Animal and Vegetable Naming Tasks 
Individual credit can be given for general category terms, like dog and terriers.  However, only 
1 point can be given when people name the same animal or vegetable at different developmental 
stages, such as sheep and lamb.  
 
Sager MD, MA; Hermann PhD, BP; LaRue PhD, A; Woodard PhD, JL, Screening for 




Center for Epidemiologic Studies Depression Scale (CES-D)©, NIMH 
 
Below is a list of the ways you might have felt or behaved. Please tell me how often you have 
felt this way during the past week. 
 
          During the Past Week 
 
Rarely or none 
of the time (less 
than 1 day) 
Some or a little 
of the time (1-2 
days) 
Occasionally or a 
moderate amount 
of time (3-4 days) 
Most or all of 




SCORING: Zero points for answers in the first column, 1 point for answers in the second 
column, 2 points for answers in the third column, and 3 points for answers in the fourth 
column.  The scoring of positive items is reversed.  Possible range of scores is zero to 60, with 
higher scores indicating the presence of more symptomatology. 
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DIGIT SYMBOL SUBSTITUTION TEST  
  
1. Background and rationale  
  
The Digit Symbol Substitution Test (DSST) may be a more sensitive measure of dementia 
than the MMSE.  The DSST requires response speed, sustained attention, visual spatial skills 
and set shifting.  It is part of the Wechsler Adult Intelligence Scale, one of the most widely 
used measures of intelligence.  It has been associated with subsequent mortality, 
independent of comorbidity in the CHS cohort.1  
  
The DSST requires that the participant fill in a series of symbols correctly coded within 90 
seconds.  In this test, the higher the score, the better the person’s performance.  
 
2. Equipment and supplies  
  
• No. 2 pencils with eraser  
• Stop watch  
• DSST task sheet  
• Scoring template for DSST  
  
 3. Safety issues and exclusions  
  
 None  
  
 4. Participant and exam room preparation  
  
         The DSST should be administered in a quiet place with minimal distractions at a desk or  
  table the participant can use to write on.  Unless it is policy at the clinic for examiners to  
  never knock or open a closed examination room door, we strongly encourage that a special  
  sign be posted indicating that the DSST is being administered and to please not interrupt  
  the test.  If any temporary condition that may detract the participant from their optimal  
  performance cannot be removed, the participant should be moved to another location; if  
  this is not possible, reschedule the exam.  
   
  Ask the participant if they are comfortable.  Reassure them that this is a routine test of   
  concentration that will be done several times during the course of the study.    
 
5. Detailed measurement procedures  
        
           5.1 General issues/description  
  
    This is a standard neuropsychologic test.  The participant completes the task of recording    
    the symbols that correspond to a series of digits.  The task is timed.  This is a pencil and  
    paper task.  The participant practices on a sample, copying the correct symbol given for  
    each number.  The participant then is timed on the actual task.  The score is the number  
    correct in 90 seconds.  
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• It is imperative to review the instructions very deliberately and to speak slowly, and 
for those participants who are hard of hearing, speak low, not loudly.  
  
• Be certain that participants understand the instructions before proceeding with the 
test.  
  
• Be certain that participants who wear reading glasses are wearing them.   
  
• Read the standardized script exactly as it is written.  
  
• Do not offer encouraging words or in any way distract the participant, unless they  
actually stop and need to be encouraged to continue.    
   
        5.2. Preparation for test: Determine if participant wears glasses for reading.           
  
Script: “Do you usually wear glasses to read?”  
  
If the answer is yes, ask the participant to put on their glasses.   
  
Script: “Please put on your glasses.”  
 
  5.3 Instructions  
  
1) Place the task sheet before the participant and point to the task.  
  
Script: “Look at these boxes across the top of the page.  On the top of each box 
is a number from one through nine.  On the bottom part of each box, there is a 
symbol.  Each symbol is paired with a number.”  
  
                          Point to the four rows of boxes.  
  
Script: “Down here are boxes with numbers on the top, but the bottom part is 
blank.  What I want you to do is to put the correct symbol in each box like this.”  
  
Fill in the first three sample boxes.  
 
Script: “Now I want you to fill in all boxes up to this line.”  
  
Point to the line separating the samples from the test proper.  
  
2) Let the participant attempt the sample.  
• If the participant has difficulty completing the ten sample items or does not 
understand the task, help them complete the sample items.  
• If the participant still has difficulty or does not understand the task, 
discontinue the task, and indicate on the form that the participant was unable 
to complete the sample. 
• Give participants with physical limitations (e.g., arthritis or visual 
limitations) an opportunity to complete the sample.  
Digit Symbol Substitution Test  
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• If a visually or physically impaired participant cannot complete the sample, 
check “unable to test” on the form or do not record scores.  
  
3) After the demonstration and practice is complete, point to the first box following 
the sample items and say: 
 
Script: “When I tell you to begin, start here and fill in the boxes in these four 
rows.  Do them in order and don’t skip any.  Please try to work as quickly as 
possible.  Let’s begin.”  
 
      4)  If the participant stops filling in the boxes before the 90 seconds have passed,   
           give them standard encouragement.  
 
Script: “Can you go further?”  
 
5) If the participant begins to erase filled boxes, tell the participant not to waste time  
    erasing.  
 
6) Stop the participant after 90 seconds.  (Note: do not tell them what the time limit  
     is)   
   
Script: “That’s good.  That completes this set of tasks.”  
  
 5.4 Scoring  
  
1) Indicate whether or not the participant completed the sample.  
  
• If they were not able to complete the sample (not due to a physical 
limitation, such as poor vision), check off “unable to complete sample,” 
record “00” for “number completed,” and mark “00” for “number incorrect.”  
  
• If they refused to complete the sample, check off “refused” and do not 
attempt to score the test.  
  
• If they are unable to complete the sample due to a physical limitation, such 
as poor vision, do not attempt to score the test.  
  
2) If they completed the sample, check “sample completed” and go on to the timed test.  
  
3) When it is known that a participant is dyslexic and will therefore draw some types of 
symbols backward, those symbols which are drawn exactly backward are scored as 
being correct.  
  
4) Single blank spaces between two completed items are not considered incorrectly 
coded symbols.   
  
5) Two or more blanks which occur consecutively signal the end of the task.  Symbols 
coded after two or more blanks are not included in totals recorded.  
Digit Symbol Substitution Test  
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6) Enter the number completed.  
  
7) Enter the number of symbols incorrectly coded.  
  
8) One blank space does not count as completed or as incorrect.  
  
9) Additional Scoring Notes  
  
• An “A” is not acceptable for the carat “^” sign (symbol for number 7).  
  
• A “U” with a tail is acceptable for the “U” symbol (symbol for number 5).  
  
• A flat-bottomed “U” is also acceptable for the round-bottomed “U” (symbol 
for  
number 5).  
  
6. Alert values/follow-up/reporting  
  
When testing is completed, thank the participant without offering specific feedback on their 
performance.  
  
 7. Quality assurance  
  
7.1  Training requirements  
The examiner requires no special qualifications or prior experience for performing this 
assessment.  Training should include:   
• Read and study manual  
• Attend training session on techniques (or observe administration by experienced  
examiner)  
• Practice on volunteers   
• Discuss problems and questions with local expert or QC officer  
  
7.2  Certification requirements  
• Complete training requirements  
• Conducts exam on two participants while being observed by QC officer      
• Correctly scores sample forms  
  
7.3  Quality assurance checklist   
 Exam performed in quiet, private area without interruptions  
 Participant asked if they wear reading glasses 
 Explanation of test: 
 Instructions are given clearly, concisely and slowly  
 Participant was asked if they understand testing procedure  
 Test demonstration and practice:  
 Script read exactly as written (no omission, deletions or 
substitutions) - Subtle changes allowed only if instructions need 
to be repeated.  
Digit Symbol Substitution Test  




     Version 1.0  
5/26/05  
 Demonstrated in first 3 sample boxes  
 Participant completes 10 sample items - proper aid is given if 
participant has difficult completing items.  
 Proper coding of answers for difficulty in completing or visual 
impairment  
 Test administration:  
 Script read exactly as written  
 Participant instructed to begin and asked to stop after 90 seconds  
 Scores are coded properly (# completed, # incorrect); symbols not 
counted after two blanks.   
 Reviews form for completeness  
 Correctly completes form  
8. Reference  
  
1. Fried LP, Kronmal RA, Newman AB, et al:  Risk factors for 5-year mortality in older 
adults: the Cardiovascular Health Study. JAMA 1998 Feb 25;279(8): 585-592.   
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10. Data collection form  
  
  
   
  
  
Digit Symbol Substitution Test  








Page 1  
THE DIGIT MEMORY TEST 
Adopted from Martin Turner 
   
Digits forwards  
  
Start  Item A  
  
Finish                  Failure on both trials of a pair.   
  
Directions          “Listen carefully as I say some numbers.  When I finish, you say them.”  
  
Delivery  Digits should be given at the rate of one per second.  Administer both 
trials of each item.  Recite digits in an even monotone without any 
variation in pitch of voice.  
  
Scoring  The individual’s score is the total number of items correctly repeated 
forwards.   
  




In this example, the total correct is 5.   
  
Digits Backwards  
   
Directions  
  
Instructor will say, “Repeat these numbers after me, but this time, I want you 
to say the digits backwards.”  Give two practice trials of two digits first – any 
two numbers.  If the subject gets them wrong, correct her or him.  If the 
subject repeats the digits forwards, give a reminder that they should be 
reversed.   
Score  
  
Same as for digits forwards.  
Final score  
  
Sum total correct for backwards and forwards.  Consult Standard Score table, 
which is listed below.  This can also be expressed as a percentile equivalent, 




Most people can remember two more digits forwards than they can 
backwards.  If the gap is larger than three, or smaller than one, this may be 
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DIGITS FORWARDS   
  
Item  First trial  √ or X  Second trial  √ or X  Total  
A  43    16      
B  792    847      
C  5941    7253      
D  93872    75396      
E  152649    216748      
F  3745261    4925316      
G  82973546    69174253      
H  246937185    371625948      
        Forwards score:    
   
DIGITS BACKWARDS   
  
Item  Trial one   Trial two  √ or X  Total  
A  83    29      
B  475    615      
C  2619    3852      
D  28736    59413      
E  624719    276391      
F  4183627    1586937      
G  52624197    94617385      
        Backwards score:    
  
FINAL SCORE:   
  
Total forwards and backwards:    
Standard score:    













Martin Turner   
Jacky Ridsdale   
revised 6th October 2004    
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Table 1. Estimated standard scores for digit memory performances from six years-old to 
adulthood (Adopted from Martin Turner). 
 
Age 6 7 8 9 10 11 12 13 14 15 16 Adult 
Raw score 
4 
74 57 60 56 54 55 50 48 52 52 51 50 
5 79 63 65 61 59 59 55 53 56 56 55 54 
6 85 69 70 66 64 64 59 57 60 60 59 57 
7 90 75 75 71 69 68 64 61 64 64 63 61 
8 96 81 80 76 74 73 68 66 68 68 66 64 
9 101 87 85 81 79 77 73 70 72 72 70 68 
10 106 93 90 86 85 82 77 74 76 75 74 71 
11 112 99 95 91 90 86 81 78 80 79 78 75 
12 117 105 100 96 95 91 86 83 84 83 82 79 
13 123 111 105 101 100 95 90 87 88 87 86 82 
14 128 117 110 106 105 100 95 91 92 91 89 86 
15 134 123 115 111 110 105 99 96 96 95 93 89 
16 139 129 120 116 115 109 104 100 100 98 97 93 
17 144 135 125 121 121 114 108 104 104 102 101 96 
18 150 141 130 126 126 118 112 109 108 106 105 100 
19 155 147 135 131 131 123 117 113 112 110 108 104 
20 161 153 140 136 136 127 121 117 116 114 112 107 
21   145 141 141 132 126 122 120 118 116 111 
22   150 146 146 136 130 126 124 121 120 114 
23   155 151 152 141 134 130 128 125 124 118 
24   159 156 157 145 139 134 132 129 127 121 
25      150 143 139 136 133 131 125 
26      154 148 143 140 137 135 129 
27      159 152 147 144 141 139 132 
28      163 157 152 148 144 143 136 
29        156 152 148 147 139 
30        160 156 152 150 143 
31         160 156 154 146 
32         164 160 158 150 
33            154 
34            157 
35            161 
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54 0.1 77 6 100 50 123 94 
55 0.1 78 7 101 53 124 95 
56 0.2 79 8 102 55 125 95 
57 0.2 80 9 103 58 126 96 
58 0.3 81 10 104 61 127 96 
59 0.3 82 12 105 63 128 97 
60 0.4 83 13 106 66 129 97 
61 0.5 84 14 107 68 130 98 
62 0.6 85 16 108 70 131 98 
63 0.7 86 18 109 73 132 98 
64 0.8 87 19 110 75 133 99 
65 1 88 21 111 77 134 99 
66 1 89 23 112 79 135 99 
67 1 90 25 113 81 136 99.2 
68 2 91 27 114 82 137 99.3 
69 2 92 30 115 84 138 99.4 
70 2 93 32 116 86 139 99.5 
71 3 94 34 117 87 140 99.6 
72 3 95 37 118 88 141 99.7 
73 4 96 39 119 90 142 99.7 
74 4 97 42 120 91 143 99.8 
75 5 98 45 121 92 144 99.8 
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WHY: Dementia is a neurodegenerative disease where functional ability in 
individuals with dementia (IWD) declines over time. The majority of care costs in 
IWD are directly attributed to functional disability (Hurd, 2013). Compromised 
functional ability is unsafe for IWD, anxiety provoking for families and costly to 
health care organizations. Valid and reliable clinical information about functional 
ability can be used to individualize care and design safe and supportive 
environments thereby promoting the highest level of independence for individuals 
with dementia. Therefore, an effective and efficient method for measuring 
functional ability is important. 
BEST TOOL: The Functional Activities Questionnaire (FAQ) measures 
instrumental activities of daily living (IADLs), such as preparing balanced meals 
and managing personal finances. Since functional changes are noted earlier in the 
dementia process with IADLs that require a higher cognitive ability compared to 
basic activities of daily living (ADLs) (Hall, 2011; Peres et al., 2008), this tool is 
useful to monitor these functional changes over time. The FAQ may be used to 
differentiate those with mild cognitive impairment and mild Alzheimer’s disease. To 
further exemplify the importance and utilization of the FAQ, thousands of research 
participants across the United States are administered the FAQ annually as part of 
the National Alzheimer’s Coordinating Center (NACC) longitudinal research study 
taking place in 29 National Institute on Aging-funded Alzheimer’s Disease Centers 
(Weintraub et al., 2009). 
TARGET POPULATION: Older adults with normal cognition, mild cognitive 
impairment, as well as mild, moderate, and advanced dementia (Weintraub et al., 
2009). The FAQ is appropriate for clinical settings, such as acute and primary care, 
rehabilitation, assisted living, and home settings, as well as for research. 
VALIDITY AND RELIABILITY: In IWD the FAQ is a consistently accurate 
instrument with good sensitivity (85%) to identify an individual’s functional 
impairment. The FAQ demonstrates high reliability (exceeding 0.90). Tests of 
validity have been performed on the FAQ establishing it as an instrument for the 
bedside and research because it can discriminate among different functional levels 
of individuals, predict neurological exam ratings and mental status scores such as 
 
 
the Folstein Mini-Mental Status Examination (MMSE) and demonstrate sensitivity 
to change (Assis, 2014; Malek-Ahmadi, 2015; Pfeffer, 1982). 
STRENGTHS AND LIMITATIONS: The FAQ is efficient to administer to older 
adults giving consistent results across different professionals and settings including 
primary care settings, as well as with different forms of dementia (Mayo, 2013; 
Tabert et al., 2002). As with other instruments that measure functional activities 
using indirect approaches, there may be over or under estimation of abilities because 
of the lack of direct observations. 
FOLLOW-UP: Continued monitoring of IADLs in IWD is important to ensure 
environmental adaptations keeping these individuals safe. The measurement of 
IADLs is also important for advancing science. Therefore, the FAQ is an important 
measure for clinicians and researchers. 
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Functional Activities Questionnaire 
Administration 
Ask informant to rate patient’s ability using the following scoring system: 
• Dependent = 3 
• Requires assistance = 2 
• Has difficulty but completes task independently = 1 
• Normal = 0 
• Never did [the activity] but now can = 0 
• Never did and would now have difficulty = 1 
 
1.  Writing checks, paying bills, balancing checkbook  
2.  Assembling tax records, business affairs, or papers  
3.  Shopping alone for clothes, household necessities, or groceries  
4.  Playing a game of skill, working on a hobby  
5.  Heating water, making a cup of coffee, turning off stove after 
use 
 
6.  Preparing a balanced meal  
7.  Keeping track of current events  
8.  Paying attention to, understanding, discussing TV, book, 
magazine 
 
9.  Remembering appointments, family occasions, holidays, 
medications 
 
10.  Traveling out of neighborhood, driving, arranging to take 
buses 
 
 TOTAL SCORE:  
Evaluation 
Sum scores (range 0-30).  Cut-off point of 9 (dependent in 3 or more activities) is 







Pfeffer, R.I., Kurosaki, T.T., Harrah, C.H. Jr., Chance, J.M., & Filos, S. (1982). Measurement of 
functional activities in older adults in the community. Journal of Gerontology, 37(3), 323-329.  
Reprinted with permission of Oxford University Press. 
 
 
   
 
 










Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)© 
  
Instructor will say the following: 
“Now, we want you to remember what your friend or relative was like 10 years-ago and to compare 
it with what he/she is like now today.  10 years-ago was in (write down the year).  Below are 
situations where this person has to use his/her memory or intelligence and we want you to indicate 
whether this has improved, stayed the same, or got worse in that situation over the past 10 years.  
Note the importance of comparing his/her present performance with 10 years ago.  For example, if 
10 years ago this person always forgot where he/she had left things, and he/she still does, then this 
would be considered 'Hasn't changed much'.  Please indicate the changes you have observed by 
circling the appropriate answer.” 
 











   
   
   
   
   
   
   
   
 
 




Instructor will say the following:  
“I’m going to give you a letter of the alphabet and ask you to name as many different words 
as you can think of that start with that letter.  I don’t want you to include names of people or 
places.  You’ll have one minute to think of as many different words as you can.  Try not to 
give the same words with different endings, like for example, run, runner and running.”  
  
“Now go ahead and tell me all the different words that you can think of that start with the 
letter F.”  
  
Repeat the above instructions for the letters A and S.  
  
  
SCORING LETTER FLUENCY  
  
1) Scoring Tip: Consult a dictionary to see if the word given is a noun.  As a rule of thumb, if 
the word has a separate entry to a similar word, as for pill and pillbox, it is scored as a correct 
response.  
2) Sum the total number of correct responses. 
3) Note the corresponding times the answers are provided 
4) Compute reaction times by calculating the mean time interval between the first word 


























Patterson J. (2011) F-A-S Test. In: Kreutzer J.S., DeLuca J., Caplan B. (eds) 











   
The Neuropsychiatric Inventory–Questionnaire:  
Background and Administration  
  
  
  The Neuropsychiatric Inventory–Questionnaire (NPI-Q) was developed and cross-validated 
with the standard NPI to provide a brief assessment of neuropsychiatric symptomatology in routine 
clinical practice settings (Kaufer et al, J Neuropsychiatry Clin Neurosci 2000, 12:233-239).  The 
NPI-Q is adapted from the NPI (Cummings et al, Neurology 1994; 44:2308-2314), a validated 
informant-based interview that assesses neuropsychiatric symptoms over the previous month.  The 
original NPI included 10 neuropsychiatric domains; two others, Nighttime Behavioral 
Disturbances and Appetite/Eating Changes, have subsequently been added.  Another recent 
modification of the original NPI is the addition of a Caregiver Distress Scale for evaluating the 
psychological impact of neuropsychiatric symptoms reported to be present (Kaufer et al, JAGS, 
1998;46:210-215).  The NPI-Q includes both of these additions.  
  
  The NPI-Q is designed to be a self-administered questionnaire completed by informants about 
patients for whom they care. Each of the 12 NPI-Q domains contains a survey question that 
reflects cardinal symptoms of that domain.  Initial responses to each domain question are "Yes" 
(present) or "No" (absent).  If the response to the domain question is "No", the informant goes to 
the next question.  If "Yes", the informant then rates both the Severity of the symptoms present 
within the last month on a 3-point scale and the associated impact of the symptom manifestations 
on them (i.e. Caregiver Distress) using a 5-point scale.  The NPI-Q provides symptom Severity and 
Distress ratings for each symptom reported, and total Severity and Distress scores reflecting the 
sum of individual domain scores.  
  
Most informants will be able to complete the NPI-Q in 5 minutes or less.  It is 
recommended that responses to the NPI-Q be reviewed for completeness by a clinician and for 
clarifying uncertainties after each administration.  The first time an informant completes the NPIQ, 
it may be useful to verbally review the instructions.  In some instances, it may be necessary to 
conduct the NPI-Q in part or entirely as an interview.  
  
The NPI and NPI-Q are both copyright-protected by Jeffrey L. Cummings, MD.  The NPI-Q was 
developed by Daniel Kaufer, MD with permission.  Use of the NPI or NPI-Q in investigational 
studies sponsored in whole or part by for-profit entities is prohibited without express written 
consent.  
  
For inquiries regarding the NPI-Q, contact:  
  
   Jeffrey L. Cummings, MD  
                   Mary S. Easton Center for Alzheimer's Disease Research  
      10911 Weyburn Ave; #200       
      Los Angeles, CA 90095  
   jcummings@mednet.ucla.edu  
  
   The NPI-Q can be found at:  






Please answer the following questions based on changes that have occurred since the 
patient first began to experience memory problems.  
 
Circle "Yes" only if the symptom(s) has been present in the last month.  Otherwise, 
circle "No".  For each item marked "Yes":  
  
a) Rate the SEVERITY of the symptom (how it affects the patient):      
      1 = Mild (noticeable, but not a significant change)    
2 = Moderate (significant, but not a dramatic change)  
3 = Severe (very marked or prominent, a dramatic change)  
  
b) Rate the DISTRESS you experience due to that symptom (how it affects 
you):  
0 = Not distressing at all  
1 = Minimal (slightly distressing, not a problem to cope with)  
2 = Mild (not very distressing, generally easy to cope with)  
3 = Moderate (fairly distressing, not always easy to cope with)  
4 = Severe (very distressing, difficult to cope with)  
5 = Extreme or Very Severe (extremely distressing, unable to cope with)   
      
 Please answer each question carefully.  Ask for assistance if you have any questions.  
  
Does the patient have false beliefs, such as thinking that others 
are stealing from him/her or planning to harm him/her in some 
way?  
  
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
  
Does the patient have hallucinations such as false visions or 
voices?  Does he or she seem to hear or see things that are not 
present?  
   
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
  
Agitation/Aggression  Is the patient resistive to help from others at times, or hard to 
handle?  
  
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
    
Depression/Dysphoria Does the patient seem sad or say that he /she is depressed?   
  
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
  
Does the patient become upset when separated from you?  Does 
he/she have any other signs of nervousness, such as shortness of 
breath, sighing, being unable to relax, or feeling excessively 
tense?  
Delusions  
Hallucinations   
Anxiety    
 
 
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
                 
Does the patient appear to feel too good or act excessively 
happy?  
   
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
  
Does the patient seem less interested in his/her usual activities or 
in the activities and plans of others?  
   
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
  
Does the patient seem to act impulsively, for example, talking to 
strangers as if he/she knows them, or saying things that may hurt 
people's feelings?  
   
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
  
Is the patient impatient and cranky?  Does he/she have difficulty 
coping with delays or waiting for planned activities?  
   
 Yes       No     SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
    
Does the patient engage in repetitive activities such as pacing 
around the house, handling buttons, wrapping string, or doing 
other things repeatedly?  
   
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
  
   
Does the patient awaken you during the night, rise too early in 
the morning, or take excessive naps during the day?   
   
  
 Yes       No    SEVERITY:   1    2    3   DISTRESS:   0   1    2    3    4    5  
    
Has the patient lost or gained weight or had a change in the type 
of food he/she likes?  
  











Disinhibition   
Irritability/Lability  
Motor Disturbance  





   







Delusions       0      1      2      3     0     1     2     3     4     5  
Hallucinations       0      1      2      3     0     1     2     3     4     5  
Agitation/Aggression      0      1      2      3     0     1     2     3     4     5  
Dysphoria/Depression       0      1      2      3     0     1     2     3     4     5  
Anxiety       0      1      2      3     0     1     2     3     4     5  
Euphoria/Elation       0      1      2      3     0     1     2     3     4     5  
Apathy/Indifference       0      1      2      3     0     1     2     3     4     5  
Disinhibition       0      1      2      3     0     1     2     3     4     5  
Irritability/Lability       0      1      2      3     0     1     2     3     4     5  
Aberrant Motor       0      1      2      3     0     1     2     3     4     5  
Nighttime Behavior       0      1      2      3     0     1     2     3     4     5  
Appetite/Eating       0      1      2      3     0     1     2     3     4     5  
























Trail Making Test (TMT) / Trails “A” & “B” 
    
  
  
This test of cognitive function has two parts: Trails “A” and “Trails B.” Trials A requires the 
individual to connect a sequence of 25 numbers in order.  Trails “B” requires the individual to 
alternately connect a sequence of 25 numbers and letters (e.g. 1-A-2-B-3-C, etc.).   
  
  Trail Making Test (TMT) / Trails “A” & “B” 
Link to Tool   http://www.sagelink.ca/uploads/tools/TrailMakingTestAB.pdf 
Time to  
Administer  
2 – 5 minutes  
Type  Standardized Screening Tool  
  
Setting  Primary care.  
  
Administration  Trail Making Part A:  
1. Provide the person with the sample Trails A first.  Once completed correctly, 
then move on to the actual Trails A.  
2. Instruct the individual to “Please draw a line connecting the numbers 1, 2, 3, 4 
etc. in order until you reach the end.  Try to draw the lines as fast as you can.”   
3. If the person makes a mistake on the sample Trails A, point it out to them and 
explain the error.  Repeat the sample Trails A until they have completed it 
correctly or it becomes evident that they are unable to do the task.  
4. Once the sample trails A has been completed correctly, give them the real Trails 
A.  Repeat the instructions as given in step two.  
5. Start timing the test as soon as the instruction is given to begin the test.   
  
Trail Making Part B:   
1. Provide the individual with the sample Trails B.  Once they have completed it 
correctly, then move on to the actual Trails B.   
2. Instruct the individual that this second part of the test is slightly more difficult as 
it requires them to alternate between numbers and letters.  Instructor will say, 
“On this page are some numbers and letters.  Begin at 1 and draw a line from 1 
to A, A to 2, 2 to B, and so forth until you reach the end.  Remember first you 
have a number, then a letter, then a number, and so on.  Draw the lines as fast as 
you can.”   
3. If the person makes a mistake on the sample Trails B, point out the error and 
explain why it is incorrect.  Repeat this procedure until the task is performed 
correctly or it becomes apparent that they cannot complete the task.   
4. After the person has completed the sample Trails B, provide them with the actual 
Trails B.  Repeat the instruction given in step 2.  Timing begins as soon as the 
person is told to begin.   
5. Be alert for mistakes.  If the person makes a mistake, point it out to them 
immediately, return the person to the last correct circle, and continue the test 
from that point.  Continue timing and record the number of errors made until 
task is completed.   
 
 
Interpretation  1. Part A and B are scored separately.  The score for each part is the number of seconds 
required to complete the task.  
2. More than 1 error or a score below the 10th percentile in time (seconds) raises 
concerns.  Scores are compared against the 50th percentile.  
3. Generally, time over 3 minutes or more than 1 error is a failure. 
 
   
   
Reference  Corrigan J.D., Hinkeldey M.S. (1987). Relationships between parts A and B of the Trail 
Making Test. JClin Psychol., 43(4), 402–409.  
Gaudino E.A., Geisler M.W., Squires N.K. (1995). Construct validity in the Trail 
Making Test: what makes Part B harder? J Clin Exp Neuropsychol., 17(4), 529-535.  
Lezak M.D., Howieson D.B., Loring D.W. (2004).  Neuropsychological Assessment. 
4th ed. New York: Oxford University Press; 2004.  
Reitan R.M. (1958). Validity of the Trail Making test as an indicator of organic brain 


























CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT 
 
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN HOSPITAL: 
Hospital Research Unit 
 
Study Title: Brain Training and Meditation’s Effects on Memory in Seniors with Vascular 
Cognitive Impairment 
Principal Investigator: Dr. Salardini 
Funding Source: None 
 
Invitation to Participate and Description of Project 
You are invited to participate in a research study designed to look at two safe, non- 
pharmacological interventions effects on slowing cognitive decline in Vascular Cognitive 
Impairment. 
You have been asked to participate because we are seeking participants between the ages 
of 60- 89 who have mild cognitive impairment (MCI) due to cerebral small vascular disease 
(CSVD), and we would like to provide you an intervention that may slow the progression of 
certain cognitive declines that are common in this disease, like problem-solving capabilities. The 
study will be conducted at Yale New Haven Hospital Research Unit. 
In order to decide whether or not you wish to be a part of this research study, we want 
you to carefully review its risks and benefits to make an informed decision. This consent form 
includes the study’s purpose, its procedures and associated risks, possible benefits, and possible 
alternative treatments. If you still wish to participate in the study after reviewing this document, 
we ask that you sign this form. 
 
Description of Procedures 
 
If you agree to join this study, you will be asked to play a computer game and to engage in a 
relaxing activity. A description of this clinical trial will be available on 
http://www.ClinicalTrials.gov, as required by U.S. Law. The site may post a summary of our 




Participants enrolled in the combined mindfulness meditation (MM) and Dual N-Back 








Participants who are randomized and allocated to the low-intensity intervention are 
offered tuition for playing solitaire and listening to selected music for a total of one-hour per day. 
Participants will be expected to play 30 minutes of solitaire followed by 30 minutes of listening to 
relaxation music for 12 weeks. 
Participants will be expected to follow this same protocol on days that they are not at 
clinic. These activities will be placed on a server onto which they will need to log onto to have 
their compliance recorded. For those with less than 80% compliance on a weekly basis, one 
warning will be given, followed by dys-enrollment from the study if low compliance continues. 
Groups session will be mandatory during the first two weeks of the study, but after that, the 
subjects may do the exercises at home if they wish. 
 
Risks and Inconveniences 
Experimental studies may involve potential and unforeseeable risks that include physical harm or 
loss of confidentially. To mitigate potential harm, we have created a list of potential risks and 
corresponding action plans to address them should they occur. 
 
Risks of Magnetic Resonance Imaging (MRI) 
Magnetic resonance (MR) imaging is a technique that uses magnetism and radio waves to 
take pictures and measure chemicals of different parts of the body. The United States Food and 
Drug Administration (FDA) has set guidelines for magnet strength and exposure to radio waves, 
and we will carefully observe those guidelines. 
MRI is usually a harmless procedure; however, risks can occur. On rare occasions, some 
people may feel uncomfortable or anxious due to claustrophobia or may develop dizziness, an 
upset stomach, a metallic taste, tingling sensations, or muscle twitches. These sensations usually 
go away quickly, but please inform the research staff if you have them. 
People with metal objects both inside or physically on their bodies are at greatest risk for 
harm because the MRI’s strong magnets will harm you. To minimize these risks, the exclusion 
criteria includes people with pacemakers, metal pieces inside their body, aneurysm clips, large 
colored tattoos, or any other contraindications for MRI, and people who are claustrophobic. To 
lower the risk of harm from metal objects, each participant will be scanned by a metal detector 
every time before entering the MRI room. No metal objects will be present in the MRI rooms and 
doors will remained closed during sessions to prevent metal objects from the outside entering the 
room. During the MRI study, participants will be provided earplugs and closely monitored. 
 
 
Should a participant become anxious or experience any adverse event, the MRI study will be 
discontinued and rescheduled for a later time, if it is not contraindicated. 
We want participants to be aware of the risks and harms associated with MRI’s, so we 
request that participants read and answer the questions on the MRI Safety Questionnaire. 
Participants will be required to sign and hand-in the completed Questionnaire. 
MRI results are for research purposes only. Only in the event of a concerning finding, 
will the image be reviewed by a certified, practicing radiologist at our facility to provide a 
diagnostic evaluation of the image. Based on the radiologist’s impression, the PI will inform the 
subject of the finding and recommend that the participant seek his or her primary care provider 
for further medical advice. We, the investigators, the Magnetic Resonance Research Center, and 
Yale University are not responsible for further treatment. 
 
Risks of Intravenous Catheter Placement and Gadolinium Contrast 
Having an intravenous (IV) line placed is benign procedure. Though, standard risks 
include mild pain, infection, bruising, or clot formation. To minimize these risks, registered 
nurses will be performing these tasks and using proper technique. A total of 200 mL of blood will 
be collected during the entire study. Should an adverse event occur, participants will receive 
appropriate medical arrangements from a licensed health care health provider. 
Gadolinium is an FDA approved contrast that is used in MRI imaging. This contrast is 
safe in participants with good kidney function, and very rarely do people experience an adverse 
reaction. 
Gadolinium risks are greatest in people with kidney dysfunction because it could 
potentially cause a life-threatening disease Nephrogenic Systemic Fibrosis/Nephrogenic 
Fibrosing Dermopathy (NSF/NFD). To avoid this risk, participants who have a glomerular 
filtration rate (eGFR) of <30 mL/min/1.73 m2, receive dialysis, or have acute kidney injury will 
not be included in this study. Detailed information on the contrast agent Gadolinium can be 
provided to you at your request. 
 
Risks of Discontinuation of Pharmaceuticals 
The inclusion criteria requests that participants not be on anti-anxiolytics or medications 
that alter cognition six weeks prior to the start of the study. These medications include 
tranquilizers, anti- anxiolytics, hypnotics, ionotropic, cholinomimetic agents, cholinesterase 
inhibitors, or NMDA antagonists. These medications would confound outcome measurements in 
our study. Participants who have relative contraindications in discontinuation of medications will 
not be included. 
 
 
The risks of discontinuing these drugs are unknown. We cannot predict the risk of 
cognitive decline since there is no standard of care in mild-VCI treatment, only it is common 
practice to prescribe medications that are used in AD. Cholinesterase inhibitors are an off-label 
treatment because their benefits on cognitive outcomes or slowing disease progression is not 
supported by empirical evidence.1 
In the advent that participants unexpectedly present with worsening cognitive 
impairments, he or she can choose to opt-out-of the study and receive donepezil or no treatment 
at all. Participants are able to withdraw from the study at any time, and his or her relationship 
with Yale Hospital will not be adversely affected. 
Once the study is complete, the treatment with significantly better outcomes will be 
available to participants. 
 
Risks of Worsening Cognitive Impairment Symptoms 
Participants will be monitored for progressive cognitive decline that could potentially by 
exacerbated by our interventions or screening protocol. In the event that a participant experiences 
an abrupt decline from baseline, the participant will be evaluated by a neurologist at our clinic 
who is licensed to address changes in cognition and activities of daily living (ADL). These 
patients will be seen within 48-hours of onset of symptoms and appropriate medical arrangements 
will be made. We will track these participants until resolution. In the event that the decline is so 
severe that the participant’s surrogate can no longer care for him or her, that participant will be 
admitted to the hospital and appropriate medical interventions will be provided, in addition to 
case management. We will track these participants until resolution. This risk is highly unlikely. 
 
Risk of Fatigue 
The intervention is one-hour in duration daily, which may cause participants to become 
fatigued. To avoid this, participants will be provided breaks as needed. Other ways we can 
mitigate fatigue is by splitting the sessions into smaller periods or provide longer rest breaks. 
 
Risks of the Screening and Evaluation Process 
The screening process requires us to ask personal psychiatric and medical history, which 
may make participants feel uncomfortable. To mitigate this risk, the screening process will only 
be conducted by trained and experienced research assistants who are able to conduct interviews in 




Risks of Inconvenience 
The study should be relatively convenient for participants. Participants will only have to 
engage in their assigned activity for a total of one hour each day. Coming to the research unit may 
be inconvenient but participants are only required to come to the clinic three times per week for 
the first two weeks and on days that outcome measurements are collected. 
 
Benefits 
The low risks associated with this study are outweighed by its potential benefits. The 
current treatment options in CSVD are poor, as it is common practice to prescribe off-label, AD 
medications. 
The non-pharmacological interventions are harmless and some have shown to promote 
plasticity and functional network strengthening that may be able to improve functional and 
cognitive deficits. Participants will have the opportunity to help us learn more about these 
interventions neuroplastic effects by agreeing to undergo functional magnetic resonance imaging. 
The knowledge gained from our study could also lead to new treatment options in CSVD. 
 
Economic Considerations 
Participants will not be charged for any medical interventions that he or she receive in the 
study. Participants will need to own a computer device to play the computer game. Also, subjects 
will receive $5 per session and can receive a total compensation of $420 upon completing the 84 
sessions. They will receive a further $100 for completing both baseline and follow-up testing, 
which includes MRIs and neuropsychological testing. According to the rules of the Internal 
Revenue Service (IRS), this payment may be considered taxable income. 
 
Treatment Alternatives/Alternatives 
The current guidelines from the American Academy of Neurology (AAN) in the 
treatment of mild cognitive impairment suggest that “Grade A” practice is to discuss with patients 
the option of cholinesterase inhibitors; however, clinicians must emphasize to patients that they 
are an off-label treatment because their benefits on cognitive outcomes or slowing disease 
progression is not supported by empirical evidence.1 “Grade B” practices are to not offer 
cholinesterase inhibitors or to add twice-weekly exercises into overall management.1 A “Grade 
C” practice is to recommended cognitive interventions because they may improve cognitive 
functioning.1 Guidelines also suggest that it is good practice to assess and treat comorbid, 
behavioral and neuropsychiatric symptoms because of their association with greater functional 
impairments2 and increased risk for disease progression.3,4 Other primary interventions that are 
 
 
being studied are aerobic exercise and lifestyle modifications, such as diet, exercise, and reducing 
blood pressure. 
In this study, participants will be asked to play a computer game and to engage in a 
relaxing activity. In the advent that participants unexpectedly present with worsening cognitive 
impairments, he or she can choose to opt-out-of the study and receive donepezil or no treatment 
at all. Once the study is complete, the treatment with significantly better outcomes will be 
available to participants. 
 
 Confidentiality 
Members of the research team will be collecting protected health information, including 
medical information and some HIPAA identifiers, throughout this study for the sole purpose of 
research and medical charting. Upon participants signed consent, we will be able to access and 
collect information about your personal health history, which includes current and past medical 
history, medications, psychiatric and substance use history, family history, and diagnostic lab 
results. During the screening process, the HIPAA identifiers that will be obtained include names, 
telephone numbers, and medical record numbers. This information will remain confidential and 
protected, but adverse effects could potentially occur should confidentiality be unlawfully 
breached. In the event of illegal disclosure, the event will be documented in the “accounting for 
disclosures log” and then forwarded to the Deputy HIPAA Privacy Officer. Participants will be 
subsequently made aware of the disclosure. 
To protect confidentiality, participants’ information and outcome measures will be 
collected and handled only by trained personnel from the Hospital Research Unit and Magnetic 
Resonance Imaging Center. Data will be recorded into Excel spreadsheets on a protected server. 
Both excel documents and server will be password protected. Digital data will be stored onto 
password protected databases. All electronic devices will have encrypted software and be on a 
protected server. Papers with personal information will be stored in locked-filing cabinets. Only 
researchers involved in this study will have access to passwords and filing cabinets and will have 
successfully completed HIPPA training. We will access participant information only when 
necessary. 
To help protect confidentiality, personal identifying information and results will be 
separated. Results will be published or presented in conferences as group data to avoid using 
identifying information. Unnecessary data will be shredded or permanently deleted at the earliest 
opportunity. Though, impactful data may be kept in a locked filing cabinet up to ten years but 
will only be accessible to authorized personnel. Any identifiable information that is obtained in 
 
 
connection with this study will remain confidential. Information will not be disclosed to any other 
person or entity, unless with your permission or as required by law in the interests of patient 
safety. We are legally required to disclose abuse and certain reportable diseases. Lawful 
authorities include U.S. and State Law Officials and members overseeing the research, such as 
the Institutional Review Board. Representatives from the Yale Human Research Protection 
Program and the Yale Human Investigation Committee, a committee that reviews, approves, and 
monitors research on human subjects, may inspect study records during internal auditing 
procedures. These individuals are required to keep all information confidential. 
Consent personnel includes I, Sarah Savoia, and PI, Dr. Salardini. Consent to screen for 
eligibility and participation in the study will be obtained at the Church Street Research Unit. 
We request that participants with capacity and assigned caretaker sign the HIPPA 
Authorization form in order to participate in the study. 
 
In Case of Injury 
In the event that a participant is injured or experiences an abrupt decline from baseline, 
the participant will be evaluated by a neurologist at our clinic, and we will pay and provide for 
the appropriate medical arrangements. Injuries that are non-research related will not be 
financially covered by Yale-New Haven Hospital. 
However, in the event that a concerning finding is observed on MRI, we, the 
investigators, the Magnetic Resonance Research Center, and Yale University will not be 
responsible for further treatment. The participant will be recommended to seek his or her primary 
care provider for further medical advice and treatment. 
 
Voluntary Participation and Withdrawal 
Participating in this study is voluntary, and participants are able to withdraw from the 
study at any time. Refusal to participate or withdrawal from the study will not adversely affect 
your relationship with Yale Hospital. We would still treat you with standard therapy or, at your 
request. 
 
Withdrawing from the Study 
To withdraw from the study, you can call a member of the research team at any time. The 
interventions will be discontinued and you will no longer be able to receive these interventions 
from us outside of the study. The monetary compensation will be forfeited as well. Participants 
will not be able to re-enroll into this study. 
 
 
Participants may be withdrawn from the study in the event of disease progression, 
development of serious side effects, or less than 80% adherent to protocol. 
In the event a participant is no longer a part of the study, we will immediately stop 
collecting outcome measurements and identifying information. Prior collected data may still be 
used in our study. 
Participants will be unable to withdraw their data because we will be anonymizing it and 
separating results from personal identifying information. 
You do not give up any of your legal rights by signing this form. 
 
Questions 
If you have any remaining questions about this study, please ask us before signing. 
 
Authorization 
I consent to voluntarily participate in this study after having read this document. I attest that I 
have full capacity and understand the study’s general purposes, my involvement, and the possible 
hazards and inconveniences, as they were clearly explained to me. My signature also attests to 




Name of Participant:                                                            
 
Signature:                                                                        
 
I assign,                                                     , to be my caretaker. 
 
Caretaker 
As the assigned caretaker, I voluntarily consent to let the above participant participate in this 
study after having read this document. I understand the study’s general purposes, my 
involvement, and the possible hazards and inconveniences, as they were clearly explained to me. 
For the foreseeable future, I agree to accompany the above participant to all drop-off sessions and 
procedures. 
 
Name of Designated Caretaker:                                                                
 
Signature:                                                    
 
Relationship:                                                                  
 
Date:                                            
 
 
For the Researcher 
 
 
Signature of Principal Investigator    
 
If you have further questions about this project or if you have a research-related problem, 
you may contact the Principal Investigator Dr. Salardini at (203) 785-4085. 
If after you have signed this form and you have any questions about your privacy rights, 
please contact the Yale Privacy Officer at 203-432-5919. If you would like to talk with someone 
other than the researchers to discuss problems, concerns, and questions you may have concerning 
this research or to discuss your rights as a research subject, you may contact the Yale Human 
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